<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">Lk3WrVJ6sGm3hXrrYD8qfkQ</article-id>
      <article-id pub-id-type="other">00009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000100009</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200109</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000100009</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Correla&#231;&#227;o do col&#225;geno intersticial mioc&#225;rdico do septo do ventr&#237;culo direito com a fun&#231;&#227;o ventricular em pacientes com cardiomiopatia isqu&#234;mica</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Montera</surname>
            <given-names>Marcelo Westerlund</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
          <xref ref-type="aff" rid="aff02"/>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Drumond</surname>
            <given-names>Cant&#237;dio</given-names>
          </name>
          <xref ref-type="aff" rid="aff05"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takiya</surname>
            <given-names>Cristina</given-names>
          </name>
          <xref ref-type="aff" rid="aff06"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mesquita</surname>
            <given-names>Cl&#225;udio Tinoco</given-names>
          </name>
          <xref ref-type="aff" rid="aff03"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dohmann</surname>
            <given-names>Hans Fernando R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff04"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mady</surname>
            <given-names>Charles</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff04">
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <institution content-type="orgname">Hospital Pr&#243;-Card&#237;aco</institution>
        <institution content-type="orgdiv1">Centro de Insufici&#234;ncia Card&#237;aca </institution>
        <institution content-type="orgdiv2">Laborat&#243;rio de Cateterismo Card&#237;aco</institution>
        <country country="BR">Brasil</country>
      </aff>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Instituto do Cora&#231;&#227;o </institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff02">
        <institution content-type="orgname">Hospital Pr&#243;-Card&#237;aco</institution>
        <institution content-type="orgdiv1">Centro de Insufici&#234;ncia Card&#237;aca </institution>
        <country country="BR">Brasil</country>
      </aff>
      <aff id="aff03">
        <institution content-type="orgname">Hospital Pr&#243;-Card&#237;aco</institution>
        <institution content-type="orgdiv1">Centro de Insufici&#234;ncia Card&#237;aca </institution>
        <institution content-type="orgdiv2">Laborat&#243;rio de Medicina Nuclear</institution>
        <country country="BR">Brasil</country>
      </aff>
      <aff id="aff06">
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">Rio de Janeiro</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Federal do Rio de Janeiro</institution>
        <institution content-type="orgdiv1">Departamento de Histologia </institution>
        <country country="BR">Brazil</country>
      </aff>
      <aff id="aff05">
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <institution content-type="orgname">Santa Casa de Miseric&#243;rdia</institution>
        <institution content-type="orgdiv2">Departamento de Cardiologia</institution>
        <country country="BR">Brasil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>01</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>1</issue>
      <fpage>54</fpage>
      <lpage>62</lpage>
      <history>
        <date date-type="rev-recd">
          <day>18</day>
          <month>02</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>29</day>
          <month>11</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>03</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: O conte&#250;do de col&#225;geno intersticial (CI) no mioc&#225;rdio exerce influ&#234;ncia no relaxamento e na contra&#231;&#227;o ventricular. A sua rela&#231;&#227;o com a fun&#231;&#227;o ventricular em pacientes (pcts) com cardiomiopatia isqu&#234;mica (CMPI) n&#227;o est&#225; plenamente estudada em humanos. OBJETIVO: Avaliar a rela&#231;&#227;o da quantidade de CI nas &#225;reas n&#227;o-infartadas no septo do ventr&#237;culo direito com a fun&#231;&#227;o ventricular na CMPI. M&#201;TODOS: 31pcts com doen&#231;a arterial coronariana foram classificados em quatro grupos: Grupo C (Controle): 7pcts com as fra&#231;&#245;es de eje&#231;&#227;o dos ventr&#237;culos esquerdo (FEVE) e direito (FEVD) normais; Grupo 1: 5 pcts com FEVD &lt; 40%;Grupo 2: 9 pcts com FEVE &lt; 40%; Grupo 3: 10 pcts com disfun&#231;&#227;o de ambos os ventr&#237;culos. A FEVD e a FEVE foram calculadas por meio da angiocardiografia radionucl&#237;dica. As amostras para an&#225;lise do %CI foram obtidas por meio de bi&#243;psia endomioc&#225;rdica do ventr&#237;culo direito e coradas pela t&#233;cnica do picrosirius red. RESULTADOS: A m&#233;dia do %CI foi significativamente maior no grupo 3 quando comparada com o grupo-c e com os grupos 1 e 2 (30,2 &#177; 7,9% vs. 6,8 &#177; 3,3% vs. 15,8 &#177; 4,1% vs. 17,5 &#177; 7,7%, respectivamente; p = 0,0001). O %CI foi tamb&#233;m significativamente maior nos pacientes do grupo 2 quando comparado com o controle(17,5 &#177; 7,7% vs. 6,8 &#177; 3,3%, p = 0.0001). O %CI apresentou correla&#231;&#227;o inversa com a FEVD (r = -0,50, p = 0.003) e FEVE (r = -0,70, p = 0,0001). CONCLUS&#195;O: Na CMPI, o %CI encontra-se elevado nas &#225;reas n&#227;o-infartadas no septo do ventr&#237;culo direito e apresenta correla&#231;&#227;o inversa com o a fun&#231;&#227;o ventricular direita e esquerda.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Isquemia mioc&#225;rdica</kwd>
        <kwd>baixo d&#233;bito card&#237;aco</kwd>
        <kwd>fun&#231;&#227;o ventricular direita</kwd>
        <kwd>fun&#231;&#227;o ventricular esquerda</kwd>
        <kwd>col&#225;geno</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>04</day>
        <month>02</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO ORIGINAL</bold>
    </p>
    <p>
      <bold>Correla&#231;&#227;o do col&#225;geno intersticial mioc&#225;rdico do septo do ventr&#237;culo direito com a fun&#231;&#227;o ventricular em pacientes com cardiomiopatia isqu&#234;mica</bold>
    </p>
    <p>
      <bold>Marcelo Westerlund Montera<sup>I</sup><sup>,</sup><sup>II</sup><sup>,</sup><sup>III</sup>; Cant&#237;dio Drumond<sup>V</sup>; Cristina Takiya<sup>VI</sup>; Cl&#225;udio Tinoco Mesquita<sup>III</sup>; Hans Fernando R. Dohmann<sup>IV</sup>; Charles Mady<sup>I</sup></bold>
    </p>
    <p><sup>I</sup>Universidade de S&#227;o Paulo, Instituto do Cora&#231;&#227;o (InCor), S&#227;o Paulo, SP - Brasil </p>
    <p><sup>II</sup>Hospital Pr&#243;-Card&#237;aco - Centro de Insufici&#234;ncia Card&#237;aca - Brasil </p>
    <p><sup>III</sup>Hospital Pr&#243;-Card&#237;aco - Centro de Insufici&#234;ncia Card&#237;aca - Laborat&#243;rio de Medicina Nuclear - Brasil </p>
    <p><sup>IV</sup>Hospital Pr&#243;-Card&#237;aco - Centro de Insufici&#234;ncia Card&#237;aca - Laborat&#243;rio de Cateterismo Card&#237;aco, Rio de Janeiro, RJ - Brasil </p>
    <p><sup>V</sup>Santa Casa de Miseric&#243;rdia - Departamento de Cardiologia, Rio de Janeiro, RJ, - Brasil </p>
    <p><sup>VI</sup>Universidade Federal do Rio de Janeiro - Departamento de Histologia, Rio de Janeiro, RJ - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> O conte&#250;do de col&#225;geno intersticial (CI) no mioc&#225;rdio exerce influ&#234;ncia no relaxamento e na contra&#231;&#227;o ventricular. A sua rela&#231;&#227;o com a fun&#231;&#227;o ventricular em pacientes (pcts) com cardiomiopatia isqu&#234;mica (CMPI) n&#227;o est&#225; plenamente estudada em humanos. </p>
    <p><bold>OBJETIVO:</bold> Avaliar a rela&#231;&#227;o da quantidade de CI nas &#225;reas n&#227;o-infartadas no septo do ventr&#237;culo direito com a fun&#231;&#227;o ventricular na CMPI. </p>
    <p><bold>M&#201;TODOS:</bold> 31 pcts com doen&#231;a arterial coronariana foram classificados em quatro grupos: Grupo C (Controle): 7pcts com as fra&#231;&#245;es de eje&#231;&#227;o dos ventr&#237;culos esquerdo (FEVE) e direito (FEVD) normais; Grupo 1: 5 pcts com FEVD &lt; 40%;Grupo 2: 9 pcts com FEVE &lt; 40%; Grupo 3: 10 pcts com disfun&#231;&#227;o de ambos os ventr&#237;culos. A FEVD e a FEVE foram calculadas por meio da angiocardiografia radionucl&#237;dica. As amostras para an&#225;lise do %CI foram obtidas por meio de bi&#243;psia endomioc&#225;rdica do ventr&#237;culo direito e coradas pela t&#233;cnica do <italic>picrosirius red</italic>. </p>
    <p><bold>RESULTADOS:</bold> A m&#233;dia do %CI foi significativamente maior no grupo 3 quando comparada com o grupo-c e com os grupos 1 e 2 (30,2 &#177; 7,9% vs. 6,8 &#177; 3,3% vs. 15,8 &#177; 4,1% vs. 17,5 &#177; 7,7%, respectivamente; p = 0,0001). O %CI foi tamb&#233;m significativamente maior nos pacientes do grupo 2 quando comparado com o controle(17,5 &#177; 7,7% vs. 6,8 &#177; 3,3%, p = 0.0001). O %CI apresentou correla&#231;&#227;o inversa com a FEVD (r = -0,50, p = 0.003) e FEVE (r = -0,70, p = 0,0001). </p>
    <p><bold>CONCLUS&#195;O:</bold> Na CMPI, o %CI encontra-se elevado nas &#225;reas n&#227;o-infartadas no septo do ventr&#237;culo direito e apresenta correla&#231;&#227;o inversa com o a fun&#231;&#227;o ventricular direita e esquerda.</p>
    <p><bold>Palavras-chave:</bold> Isquemia mioc&#225;rdica, baixo d&#233;bito card&#237;aco, fun&#231;&#227;o ventricular direita, fun&#231;&#227;o ventricular esquerda, col&#225;geno.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A insufici&#234;ncia card&#237;aca (IC) &#233; uma s&#237;ndrome que apresenta alta preval&#234;ncia, acometendo cerca de 1% a 1,5% da popula&#231;&#227;o adulta. Estima-se hoje que 4,7 milh&#245;es de americanos apresentem IC, com m&#233;dia de 400 mil novos casos a cada ano<sup>1-3</sup>. A maioria dos casos de IC se estabelece por doen&#231;a do m&#250;sculo card&#237;aco, reconhecida como cardiomiopatia. A cardiomiopatia de origem isqu&#234;mica (CMPI) &#233; a mais freq&#252;ente, representando cerca de 40% a 80% de todas as cardiomiopatias<sup>1,4</sup>. A CMPI apresenta pior progn&#243;stico evolutivo quando comparada &#224; cardiomiopatia dilatada de origem idiop&#225;tica<sup>4-7</sup>.Os poss&#237;veis fatores respons&#225;veis por esse pior progn&#243;stico seriam a presen&#231;a de &#225;reas de isquemia mioc&#225;rdica e de fibrose por infarto pr&#233;vio, que predisporiam a eventos de arritmia e a extenso processo de remodelagem ventricular.</p>
    <p>A ativa&#231;&#227;o do processo de remodelagem ventricular est&#225; relacionada com a extens&#227;o da &#225;rea de necrose, fibrose e de isquemia na regi&#227;o do infarto. No entanto, tem sido demonstrado que as altera&#231;&#245;es morfol&#243;gicas nas &#225;reas distantes da &#225;rea infartada exercem um importante papel no desenvolvimento da remodelagem ventricular<sup>8,9</sup>. Nessas &#225;reas, encontramos fibrose difusa perivascular, fibrose intersticial e atrofia difusa dos mi&#243;citos<sup>10</sup>. As altera&#231;&#245;es na matriz mioc&#225;rdica nas regi&#245;es distantes da cicatriza&#231;&#227;o do infarto representam cerca de dois ter&#231;os de todo o tecido fibroso do cora&#231;&#227;o e s&#227;o consideradas o maior componente da remodelagem ventricular na CMPI<sup>11,12</sup>.</p>
    <p>A rela&#231;&#227;o das altera&#231;&#245;es morfol&#243;gicas e morfom&#233;tricas do mioc&#225;rdio no p&#243;s-infarto, com o desenvolvimento de disfun&#231;&#245;es sist&#243;lica e diast&#243;lica do ventr&#237;culo esquerdo (VE), est&#225; bem descrita em diversos estudos da literatura<sup>8,13-16</sup>. Entretanto, a rela&#231;&#227;o das altera&#231;&#245;es na matriz do mioc&#225;rdio n&#227;o-infartado com a fun&#231;&#227;o sist&#243;lica dos ventr&#237;culos direito (VD) e esquerdo (VE) n&#227;o est&#225; bem esclarecida na CMPI.</p>
    <p>Neste estudo, temos o objetivo de avaliar a rela&#231;&#227;o do conte&#250;do de col&#225;geno intersticial obtido por meio de bi&#243;psia do septo do ventr&#237;culo direito, com a fun&#231;&#227;o sist&#243;lica dos ventr&#237;culos direito e esquerdo em pacientes com CMPI com graus vari&#225;veis de disfun&#231;&#227;o ventricular.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>No per&#237;odo de janeiro a dezembro de 2003, foram inclu&#237;dos de forma consecutiva no estudo 31 pacientes com doen&#231;a arterial coronariana evidenciada na cineangiocoronariografia, para investiga&#231;&#227;o diagn&#243;stica de dor precordial ou disfun&#231;&#227;o ventricular esquerda. Os pacientes foram distribu&#237;dos em quatro grupos, pela avalia&#231;&#227;o da fra&#231;&#227;o de eje&#231;&#227;o dos ventr&#237;culos esquerdo (FEVE) e direito (FEVD) e pela angiografia radionucl&#237;dica:</p>
    <list list-type="bullet">
      <list-item>
        <p><bold>Grupo-controle (grupo C):</bold> sete pacientes com as fun&#231;&#245;es sist&#243;licas do VE e VD preservadas.</p>
      </list-item>
      <list-item>
        <p><bold>Grupo 1:</bold> cinco pacientes com disfun&#231;&#227;o sist&#243;lica isolada do VD (FEVD &lt; 40%).</p>
      </list-item>
      <list-item>
        <p><bold>Grupo 2:</bold> nove pacientes com disfun&#231;&#227;o sist&#243;lica isolada do VE (FEVE &lt; 40%).</p>
      </list-item>
      <list-item>
        <p><bold>Grupo 3:</bold> dez pacientes com disfun&#231;&#227;o sist&#243;lica de VE e VD.</p>
      </list-item>
    </list>
    <p>Exclu&#237;ram-se os pacientes com hipertens&#227;o arterial pulmonar, doen&#231;a pulmonar obstrutiva cr&#244;nica, doen&#231;as infiltrativas ou restritivas do mioc&#225;rdio, doen&#231;as do col&#225;geno, suspeita de miocardite, infarto do mioc&#225;rdio com comprometimento septal e com suspeita de disfun&#231;&#227;o ventricular direita por cardiomiopatia do ventr&#237;culo direito. O protocolo de pesquisa foi aprovado pelo Conselho de &#201;tica de nosso hospital e descrito ap&#243;s a obten&#231;&#227;o do consentimento informado pelos pacientes.</p>
    <p>Todos os pacientes realizaram avalia&#231;&#227;o laboratorial de bioqu&#237;mica e fun&#231;&#227;o renal, eletrocardiograma (ECG) e ecocardiograma transtor&#225;cico (ECO). Os crit&#233;rios de exclus&#227;o foram a presen&#231;a de infarto do mioc&#225;rdico da regi&#227;o septal demonstrado pelo ECG e ECO, doen&#231;a valvar significativa, hipertens&#227;o arterial sist&#234;mica (press&#227;o arterial &gt; 140 x 90 mmHg), creatinina s&#233;rica acima de 1,4 mg/dl, fibrila&#231;&#227;o atrial, instabilidade cl&#237;nica com menos de duas semanas e doen&#231;a pulmonar obstrutiva cr&#244;nica.</p>
    <p>
      <bold>Cateterismo card&#237;aco</bold>
    </p>
    <p>Todos os pacientes realizaram cineangiocoronariografia pela t&#233;cnica de Sones, por meio de pun&#231;&#227;o femoral. O crit&#233;rio considerado para o diagn&#243;stico de doen&#231;a arterial coronariana foi a presen&#231;a de estenose coronariana epic&#225;rdica maior que 50% em pelo menos uma coron&#225;ria principal. Realizou-se tamb&#233;m ventriculografia em todos os pacientes.</p>
    <p>
      <bold>An&#225;lise da fun&#231;&#227;o ventricular</bold>
    </p>
    <p>As fun&#231;&#245;es ventriculares direita e esquerda foram avaliadas pela angiografia radionucl&#237;dica de equil&#237;brio e de primeira passagem. A fra&#231;&#227;o de eje&#231;&#227;o dos ventr&#237;culos esquerdo e direito foi calculada pelo m&#233;todo padr&#227;o recomendado pela Sociedade Americana de Cardiologia Nuclear<sup>17</sup>, com os limites inferiores da normalidade fixados em 40% para ambos os ventr&#237;culos. A FEVD foi obtida por meio da angiografia radionucl&#237;dica de primeira passagem. Empregou-se uma gama c&#226;mera Siemens, modelo DIACAM, acoplada a um computador ICON, para os exames de primeira passagem. O protocolo utilizado foi validado pelo <italic>Cardiovascular Nuclear Imaging Laboratory, Yale University School of Medicine</italic><sup>18</sup>. <italic>O</italic> Tc-99m foi injetado em todos os pacientes que se encontravam em repouso, para an&#225;lise da fun&#231;&#227;o ventricular. Obtiveram-se as imagens na posi&#231;&#227;o supina, com o detector da gama c&#226;mera na posi&#231;&#227;o obl&#237;qua anterior direita (20&#176; a 30&#176;). O processamento do estudo de primeira passagem foi realizado por dois m&#233;dicos nucleares de modo independente, utilizando duas regi&#245;es de interesse. Os resultados m&#233;dios da an&#225;lise da fun&#231;&#227;o dos ventr&#237;culos direito e esquerdo foram empregados para an&#225;lise estat&#237;stica. Os batimentos com contagens diast&#243;licas inferiores a 50% da contagem diast&#243;lica m&#225;xima foram exclu&#237;dos, bem como as ectopias ventriculares e os batimentos p&#243;s-ect&#243;picos. Para fins de an&#225;lise estat&#237;stica, a fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo direito normal foi considerada igual ou superior a 40%.</p>
    <p>A FEVE foi obtida por meio da angiografia planar radionucl&#237;dica de equil&#237;brio com a t&#233;cnica modificada de marca&#231;&#227;o <italic>in vivo</italic>, utilizando de 2 a 3 mg de pirofosfato estanhoso, 15 minutos antes da inje&#231;&#227;o dos 20 mCi de Tc-99m pertecnetato<sup>19</sup>. Obtiveram-se as imagens com o paciente em supino e com o detector a 45 graus em posi&#231;&#227;o obl&#237;qua anterior esquerda. Considerou-se disfun&#231;&#227;o ventricular esquerda na presen&#231;a de FEVE &lt; 40%.</p>
    <p>
      <bold>Bi&#243;psia endomioc&#225;rdica</bold>
    </p>
    <p>A bi&#243;psia endomioc&#225;rdica foi realizada por via percut&#226;nea, segundo t&#233;cnica descrita por Mason<sup>20</sup>, com a utiliza&#231;&#227;o do bi&#243;tomo da Cordis, com a retirada de quatro fragmentos do septo interventricular do ventr&#237;culo direito de cada paciente.</p>
    <p>
      <bold>An&#225;lise histol&#243;gica e quantifica&#231;&#227;o do col&#225;geno intersticial</bold>
    </p>
    <p>Os fragmentos foram fixados em formol tamponado a 10% e posteriormente inclu&#237;dos em parafina. Cortes seriados de 5 &#181;m foram recolhidos em l&#226;minas e corados pela hematoxilina-eosina, pelo tricr&#244;mico de Masson e pela t&#233;cnica Sirius Red (0.1% Sirius Red F3BA dissolvido em acido p&#237;crico saturado, pH 2,0). Foram analisados dez campos de cada amostra com lentes objetivas de 320. O volume de col&#225;geno foi determinado por meio de an&#225;lise morfom&#233;trica quantitativa das sess&#245;es coradas pelo <italic>sirus-red</italic> e pelo analisador autom&#225;tico de imagens (ImagePro Plus, vers&#227;o 4.5.1, Media Cybernetics, Silver Spring, MD, USA). As imagens para an&#225;lise foram obtidas por c&#226;mera digital (Coolpix 990, Nikon, Jap&#227;o) acoplada a microsc&#243;pio de luz Eclipse (E400, Nikon). Cada sess&#227;o foi analisada com lente objetiva de 40 x. As fibras de col&#225;geno foram marcadas pela cor azul na luz direta, e digitalizaram-se as imagens. O percentual de col&#225;geno intersticial (%CI) de cada campo analisado foi obtido pela divis&#227;o da soma de toda a &#225;rea de tecido conectivo e pela soma de toda &#225;rea do tecido conectivo com a do cardiomi&#243;cito, como demonstrado anteriormente em diversos estudos<sup>21-24</sup>.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>Para compara&#231;&#227;o dos dados quantitativos entre os quatro grupos, realizou-se a an&#225;lise de vari&#226;ncia de Kruskal-Wallis. O teste de compara&#231;&#245;es m&#250;ltiplas de Kruskal-Wallis &#233; complementar &#224; an&#225;lise de vari&#226;ncia e, por isso, foi utilizado, pois algumas vari&#225;veis n&#227;o apresentaram distribui&#231;&#227;o normal (distribui&#231;&#227;o gaussiana). Por causa do n&#250;mero pequeno de casos e para compara&#231;&#227;o de propor&#231;&#245;es (dados qualitativos) entre os grupos, foi aplicado o teste exato de Fisher.</p>
    <p>Para compara&#231;&#227;o de m&#233;dias entre dois grupos, aplicou-se o teste de Mann-Whitney. A correla&#231;&#227;o entre o percentual de col&#225;geno com as vari&#225;veis num&#233;ricas foi avaliada pelo coeficiente de correla&#231;&#227;o de Spearman. A curva ROC (<italic>receiver operator characteristic</italic>) foi utilizada para estabelecer o melhor ponto de corte do %CI, que prediz a disfun&#231;&#227;o ventricular direita e esquerda. O crit&#233;rio de determina&#231;&#227;o de signific&#226;ncia adotado foi o n&#237;vel de 5%. A an&#225;lise estat&#237;stica foi processada pelo <italic>software</italic> estat&#237;stico SAS<sup>&#174;</sup> System.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>
      <bold>Caracter&#237;sticas dos pacientes</bold>
    </p>
    <p>As caracter&#237;sticas cl&#237;nicas dos pacientes est&#227;o demonstradas na <xref ref-type="table" rid="t1">tabela 1</xref>. Nenhuma diferen&#231;a significativa foi observada entre os quatro grupos em rela&#231;&#227;o &#224;s var&#225;veis cl&#237;nicas e demogr&#225;ficas, exceto pela menor incid&#234;ncia de tabagismo no grupo 3. A maioria dos pacientes estava em uso de inibidores da enzima de convers&#227;o e betabloqueadores, sem demonstrar diferen&#231;as significativas entre os grupos quanto &#224; posologia dos medicamentos.</p>
    <p content-type="asset">
      <table-wrap id="t1">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gt01.jpg"/></table-wrap>
    </p>
    <p>
      <bold>Doen&#231;a arterial coronariana</bold>
    </p>
    <p>A maioria dos pacientes (84%) apresentava les&#245;es de dois ou tr&#234;s vasos, sendo a coron&#225;ria descente anterior a mais freq&#252;entemente acometida. N&#227;o se observou nenhuma diferen&#231;a entre os quatro grupos quanto &#224; presen&#231;a de les&#227;o proximal das coron&#225;rias descendente anterior e direita (p = 0,91) <xref ref-type="table" rid="t2">Tabela 2</xref>.</p>
    <p content-type="asset">
      <table-wrap id="t2">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gt02.jpg"/></table-wrap>
    </p>
    <p>
      <bold>An&#225;lise da fun&#231;&#227;o ventricular</bold>
    </p>
    <p>A FEVE m&#233;dia nos quatro grupos foi de 51,5 &#177; 8,5 no grupo-controle, 50,6 &#177; 8,8, 27,9 &#177; 5,1 e 21,7 &#177; 4,7% nos grupos 1 a 3, respectivamente. A FEVD m&#233;dia nos quatro grupos foi, respectivamente, de 42,4 &#177; 4,7, 28,2 &#177; 2,7, 50,3 &#177; 5,1 e 22,0 &#177; 6,5%. N&#227;o se observou diferen&#231;a significativa da FEVE entre os grupos com disfun&#231;&#227;o biventricular e com disfun&#231;&#227;o isolada do ventr&#237;culo esquerdo (21,7 &#177; 4,7% vs. 27,9 &#177; 5,1, p = 0,10). Da mesma forma, n&#227;o foi observada diferen&#231;a significativa quanto &#224; FEVD entre os grupos com disfun&#231;&#227;o biventricular e com disfun&#231;&#227;o isolada do ventr&#237;culo direito (28,2 &#177; 2,7 vs. 22,0 &#177; 6,5%, p = 0,10).</p>
    <p>
      <bold>An&#225;lise da fra&#231;&#227;o do col&#225;geno intersticial</bold>
    </p>
    <p>O valor m&#233;dio do %CI est&#225; demonstrado na <xref ref-type="fig" rid="fig1">figura 1</xref>. O grupo de pacientes com disfun&#231;&#227;o biventricular apresentou maior %CI em compara&#231;&#227;o com os grupos controle e disfun&#231;&#227;o isolada dos ventr&#237;culos direito e esquerdo (30,2 &#177; 7,9 vs. 6,8 &#177; 3,3, 15,8 &#177; 4,1 e 17,5 &#177; 7,7%, respectivamente; p = 0,0001). Os pacientes com disfun&#231;&#227;o ventricular esquerda isolada apresentaram um maior %CI do que o grupo-controle (17,5 &#177; 7,7 vs. 6,8 &#177; 3,3%, p = 0,0001), mas sem diferen&#231;a quando comparado com o grupo com disfun&#231;&#227;o isolada do ventr&#237;culo direito (17,5 &#177; 7,7 vs. 15,8 &#177; 4,1, p = 0,58). O grupo com disfun&#231;&#227;o isolada do ventr&#237;culo direito apresentou uma tend&#234;ncia a maior %CI em rela&#231;&#227;o ao observado no grupo-controle (15,8 &#177; 4,1 vs. 6,8 &#177; 3,3, p = 0,08) (<xref ref-type="fig" rid="fig2">fig. 2</xref>).</p>
    <fig id="fig1">
      <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf01.jpg"/></fig>
    <fig id="fig2">
      <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf02.jpg"/></fig>
    <p>
      <bold>Correla&#231;&#227;o entre o %CI e a fun&#231;&#227;o ventricular</bold>
    </p>
    <p>Observamos uma correla&#231;&#227;o linear inversa significativa entre o percentual de col&#225;geno e a FEVD (r = -0,50; p = 0,003, n = 31) e a FEVE (r =-0,70; p = 0,0001, n = 27). Isso significa que quanto maior for o percentual de col&#225;geno, menores ser&#227;o a FEVD e a FEVE, o que &#233; observado nas <xref ref-type="fig" rid="f3">figuras 3</xref> e <xref ref-type="fig" rid="f4">4</xref>.</p>
    <p content-type="asset">
      <fig id="f3">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf03.jpg"/></fig>
    </p>
    <p content-type="asset">
      <fig id="f4">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf04.jpg"/></fig>
    </p>
    <p>
      <bold>An&#225;lise da curva ROC</bold>
    </p>
    <p>O melhor ponto de corte do %CI para a associa&#231;&#227;o com FEVE <underline>&lt;</underline> 40% foi de 18,3%, com uma sensibilidade de 70,5% e especificidade de 90,0%, e &#225;rea de curva ROC de 0,87 (IC95%:0,7-0,9; p = 0,0001) (<xref ref-type="fig" rid="f5">figura 5 a</xref>). Para a associa&#231;&#227;o com FEVD <underline>&lt;</underline> 40%, o ponto de corte do %CI foi de 12,9%, com uma sensibilidade de 82,0% e especificidade de 64,2%, e &#225;rea de curva ROC de 0,77 (IC95%:0,59-0,9; p = 0,0009) (<xref ref-type="fig" rid="f5">fig. 5 b</xref>).</p>
    <p content-type="asset">
      <fig id="f5">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf05.jpg"/></fig>
    </p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Este &#233; o primeiro estudo em literatura realizado em humanos que demonstrou uma correla&#231;&#227;o direta entre os n&#237;veis do col&#225;geno intersticial no ventr&#237;culo direito com a fun&#231;&#227;o ventricular direita e esquerda em pacientes com cardiomiopatia isqu&#234;mica. Observamos uma correla&#231;&#227;o linear entre o %CI na regi&#227;o n&#227;o-infartada e o grau de disfun&#231;&#227;o ventricular dos ventr&#237;culos direito e esquerdo. O %CI apresentava-se aumentado em 4,4 vezes naqueles com disfun&#231;&#227;o biventricular, 2,5 vezes nos com disfun&#231;&#227;o isolada do ventr&#237;culo esquerdo e 2,3 vezes nos com disfun&#231;&#227;o ventricular direita isolada, quando comparados com os pacientes com fun&#231;&#227;o ventricular preservada, demonstrando a correla&#231;&#227;o inversa do %CI com a FEVE e FEVD. A associa&#231;&#227;o da disfun&#231;&#227;o ventricular com o grau de prolifera&#231;&#227;o de col&#225;geno intersticial foi refor&#231;ada na demonstra&#231;&#227;o de uma rela&#231;&#227;o linear inversa entre o percentual de prolifera&#231;&#227;o do col&#225;geno e a FEVD e FEVE (<xref ref-type="fig" rid="f3">fig. 3</xref> e <xref ref-type="fig" rid="f4">4</xref>). Pela analise da rela&#231;&#227;o dos diversos percentuais de col&#225;geno intersticial com a fun&#231;&#227;o ventricular, podemos determinar um ponto de corte de percentual de col&#225;geno intersticial para o progn&#243;stico de desenvolvimento de disfun&#231;&#227;o ventricular direita e de disfun&#231;&#227;o ventricular esquerda de 12,9% e 18%, respectivamente, com alta sensibilidade (82,0% e 70,5%, respectivamente) e especificidade (64,2% e 90,0%, respectivamente), e com as &#225;reas da curva ROC de 0,87 e 0,77, respectivamente, o que indica a forte correla&#231;&#227;o desses valores de corte do %IC para a discrimina&#231;&#227;o da presen&#231;a de disfun&#231;&#227;o ventricular (<xref ref-type="fig" rid="f5">fig. 5 a</xref> e <xref ref-type="fig" rid="f5">b</xref>).</p>
    <p>Estudos em animais e humanos t&#234;m demonstrado que as altera&#231;&#245;es na trama de col&#225;geno intersticial do mioc&#225;rdio na cardiomiopatia isqu&#234;mica e n&#227;o-isqu&#234;mica t&#234;m um importante papel no desenvolvimento da disfun&#231;&#227;o ventricular. Em particular, a possibilidade de que a deposi&#231;&#227;o de col&#225;geno no interst&#237;cio poderia ser um fator prim&#225;rio para o desenvolvimento da disfun&#231;&#227;o mioc&#225;rdica e n&#227;o somente um marcador<sup>8,9,12-16,25,26</sup>. Essa possibilidade &#233; enfatizada por estudos que demonstram que a remodelagem p&#243;s-infarto do mioc&#225;rdio est&#225; associada com o aumento da fibrose intersticial no mioc&#225;rdio n&#227;o-infartado e que esta se correlaciona com progressivo enrijecimento mioc&#225;rdico e conseq&#252;ente disfun&#231;&#227;o sist&#243;lica e diast&#243;lica<sup>12,13,26-28</sup>. Outra evid&#234;ncia que fortalece os nossos achados de maior prolifera&#231;&#227;o de CI na disfun&#231;&#227;o biventricular &#233; o fato de haver uma maior produ&#231;&#227;o de angiotensina no mioc&#225;rdio de pacientes com disfun&#231;&#227;o ventricular direita por hipertens&#227;o arterial pulmonar<sup>29</sup>. A dificuldade em confirmar a associa&#231;&#227;o do grau de disfun&#231;&#227;o ventricular direita ou esquerda com o n&#237;vel de prolifera&#231;&#227;o do CI reside na aus&#234;ncia de estudos em literatura de an&#225;lise do col&#225;geno em seres humanos vivos com o grau de disfun&#231;&#227;o ventricular, particularmente com a fun&#231;&#227;o ventricular direita. Um dos fatores envolvidos para justificar essa falta de evid&#234;ncias est&#225; na dificuldade dos m&#233;todos diagn&#243;sticos em avaliar com boa acur&#225;cia as fun&#231;&#245;es sist&#243;lica e diast&#243;lica do ventr&#237;culo direito.</p>
    <p>Pauschinger e cols.<sup>25</sup> demonstraram em pacientes com cardiomiopatia dilatada uma maior prolifera&#231;&#227;o de col&#225;geno intersticial naqueles com FEVE &lt; 50%, quando comparados com os pacientes com FEVE &gt; 50% (4,3 &#177; 0,1% vs. 2,7 &#177; 0,9 %, p &lt; 0,0035), o que foi associado ao aumento da rela&#231;&#227;o dos col&#225;genos dos tipos I e III.</p>
    <p>Na cardiomiopatia dilatada n&#227;o-isqu&#234;mica, tamb&#233;m se observa uma maior prolifera&#231;&#227;o do col&#225;geno intersticial<sup>30</sup>, mas num n&#237;vel inferior ao da cardiomiopatia isqu&#234;mica<sup>12,13</sup>. Esse n&#237;vel mais acentuado de prolifera&#231;&#227;o do col&#225;geno na cardiomiopatia isqu&#234;mica decorreria do processo de remodelagem ventricular induzido pelo infarto do mioc&#225;rdio, como tamb&#233;m do est&#237;mulo tr&#243;fico da isquemia mioc&#225;rdica<sup>31,32</sup>. A prolifera&#231;&#227;o excessiva do col&#225;geno intersticial provoca fibrose mioc&#225;rdica com conseq&#252;ente enrijecimento mioc&#225;rdico e disfun&#231;&#227;o diast&#243;lica, e subseq&#252;ente comprometimento da fun&#231;&#227;o sist&#243;lica<sup>8,33-36</sup>. Weber e Brilla<sup>14</sup> sugerem que a deposi&#231;&#227;o de col&#225;geno intersticial &#233; o principal determinante da redu&#231;&#227;o da capacidade de relaxamento ventricular. O ac&#250;mulo de col&#225;geno tamb&#233;m est&#225; relacionado com gravidade cl&#237;nica da insufici&#234;ncia card&#237;aca, grau de comprometimento hemodin&#226;mico, hiponatremia e necessidade de transplante card&#237;aco<sup>37</sup>. De forma inversa, os pacientes hipertensos tratados com inibidores da enzima de convers&#227;o ou bloqueadores do receptor da angiotensina demonstraram uma redu&#231;&#227;o da fibrose e hipertrofia ventricular, independentemente da redu&#231;&#227;o da press&#227;o arterial, com melhora das fun&#231;&#245;es sist&#243;lica e diast&#243;lica ventriculares, redu&#231;&#227;o da massa ventricular, arritmias card&#237;acas e melhora dos sintomas cl&#237;nicos<sup>38-40</sup>.</p>
    <p>Esses achados sugerem que a prolifera&#231;&#227;o do col&#225;geno intersticial na cardiomiopatia isqu&#234;mica atua como fator prim&#225;rio determinante da disfun&#231;&#227;o ventricular e n&#227;o somente como um marcador do grau de remodelagem ventricular. Nos pacientes com cardiomiopatia isqu&#234;mica, observa-se que o conte&#250;do de col&#225;geno encontra-se aumentado n&#227;o somente na &#225;rea do mioc&#225;rdio infartado, mas principalmente nas regi&#245;es n&#227;o-infartadas do mioc&#225;rdio<sup>8,12,16</sup>, o que foi questionado por Marijianowski e cols.<sup>41</sup> e validado por v&#225;rios outros autores<sup>37,42</sup>.</p>
    <p>Nossos achados t&#234;m importantes implica&#231;&#245;es na pr&#225;tica cl&#237;nica, pois demonstramos que nas formas menos avan&#231;adas de disfun&#231;&#227;o ventricular h&#225; um aumento significativo da prolifera&#231;&#227;o do col&#225;geno e que a sua progress&#227;o est&#225; diretamente relacionada com o agravamento da disfun&#231;&#227;o e grau de remodelagem ventricular. Esses achados sugerem que a terap&#234;utica de inibi&#231;&#227;o da produ&#231;&#227;o de col&#225;geno com inibidores da enzima de convers&#227;o, bloqueadores dos receptores da angiotensina e antagonistas da aldosterona, em fases menos avan&#231;adas de disfun&#231;&#227;o ventricular, pode vir a ter benef&#237;cio na redu&#231;&#227;o da progress&#227;o da remodelagem ventricular e da mortalidade, como j&#225; demonstrado na disfun&#231;&#227;o ventricular avan&#231;ada<sup>43-47</sup>.</p>
    <p>
      <bold>Limita&#231;&#245;es do estudo</bold>
    </p>
    <p>Algumas limita&#231;&#245;es em nosso estudo devem ser observadas. A maioria dos pacientes estava em uso de inibidores da enzima de convers&#227;o, o que pode ter afetado o conte&#250;do de col&#225;geno em decorr&#234;ncia de sua atua&#231;&#227;o de redu&#231;&#227;o da fibrose mioc&#225;rdica. Contudo, n&#227;o houve diferen&#231;a entre os grupos quanto ao uso da medica&#231;&#227;o e &#224; sua posologia. Outra limita&#231;&#227;o deste estudo foi a obten&#231;&#227;o das amostras teciduais por meio de bi&#243;psia endomioc&#225;rdica do septo do ventr&#237;culo direito, o que limitou a nossa avalia&#231;&#227;o a somente uma regi&#227;o ventricular, sem uma an&#225;lise da distribui&#231;&#227;o nas demais regi&#245;es ventriculares. Entretanto, esse tipo de an&#225;lise s&#243; seria poss&#237;vel em cora&#231;&#245;es de pacientes explantados com insufici&#234;ncia card&#237;aca terminal, o que n&#227;o era o objetivo de nosso estudo. Outro fator limitante foi a aus&#234;ncia de um grupo-controle de pacientes sem doen&#231;a coronariana com bi&#243;psia endomioc&#225;rdica, que, por raz&#245;es &#233;ticas, n&#227;o foi poss&#237;vel realizar. Contudo, o conte&#250;do m&#233;dio de col&#225;geno no grupo dos nossos pacientes com fun&#231;&#227;o ventricular preservada foi semelhante ao observado em estudos de pacientes com cora&#231;&#227;o normal sem doen&#231;a coronariana de amostras obtidas por bi&#243;psia do septo do VD<sup>48</sup> e da parede livre do VE<sup>49</sup>. A an&#225;lise da rela&#231;&#227;o dos subtipos do col&#225;geno tipo I/III nos teria fornecido informa&#231;&#245;es quanto ao potencial de reversibilidade da fibrose mioc&#225;rdica e do potencial de melhora evolutiva da fun&#231;&#227;o ventricular, como sugerido pelo estudo de Pauschinger e cols.<sup>25</sup>.</p>
    <p>Finalmente, n&#227;o avaliamos a presen&#231;a de isquemia mioc&#225;rdica, a qual poderia influenciar no grau de prolifera&#231;&#227;o do col&#225;geno, embora a extens&#227;o da doen&#231;a coronariana avaliada pela coronariografia fosse semelhante nos grupos de pacientes.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Conclu&#237;mos que, em pacientes com cardiomiopatia isqu&#234;mica, ocorre um aumento de col&#225;geno na regi&#227;o n&#227;o-infartada do septo do ventr&#237;culo direito que se correlaciona inversamente com o grau de disfun&#231;&#227;o sist&#243;lica dos ventr&#237;culos direito e esquerdo.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>Este artigo &#233; parte de tese de Doutorado de Marcelo Westerlund Montera pela Universidade de S&#227;o Paulo.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Marcelo Westerlund Montera </p>
        <p> Rua Conde de Iraj&#225;, 513 - Ipanema </p>
        <p> - 22271-020 - Rio de Janeiro, RJ - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="mmontera@uol.com.br">mmontera@uol.com.br</email>, </p>
        <p>
          <email xlink:href="mmontera@cardiol.br">mmontera@cardiol.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 29/11/07; revisado recebido em 18/02/08; aceito em 05/03/08</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Gheorghiade    M, Bonow RO. Chronic heart failure in the United States: a manifestation of    coronary artery disease. Circulation. 1998; 97: 282-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chronic heart failure in the United States: a manifestation of coronary artery disease</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>282</fpage>
          <lpage>9</lpage>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gheorghiade</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Hunt SA, Baker    DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines    for the evaluation and management of chronic heart failure in the adult: executive    summary. A report of the American College of Cardiology / American Heart Association    Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for    the Evaluation and Management of Heart Failure): developed in Collaboration    with the International Society for Heart and Lung Transplantation; endorsed    by the Heart Failure Society of America. Circulation. 2001; 104: 2996-3007.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in Collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America</article-title>
          <source>Circulation</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2996</fpage>
          <lpage>3007</lpage>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hunt</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Cinquegrani</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>GS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Levy D, Kenchaiah    S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence    of and survival with heart failure. N Engl J Med. 2002; 347: 1397-402.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Long-term trends in the incidence of and survival with heart failure</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1397</fpage>
          <lpage>402</lpage>
          <volume>347</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kenchaiah</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Benjamin</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Kupka</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>KK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Felker GM, Thompson    RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and    long-term survival in patients with initially unexplained cardiomyopathy. N    Engl J Med. 2000; 342: 1077-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1077</fpage>
          <lpage>84</lpage>
          <volume>342</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Felker</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Hare</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Hruban</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Clemetson</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Howard</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Likoff MJ, Chandler    SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure    secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol.    1987; 59: 634-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1987</year>
          </date>
          <fpage>634</fpage>
          <lpage>8</lpage>
          <volume>59</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Likoff</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Chandler</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Kay</surname>
              <given-names>HR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Franciosa JA,    Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular    failure due to either coronary heart disease or idiopathic dilated cardiomyopathy.    Am J Cardiol. 1983; 51: 831-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1983</year>
          </date>
          <fpage>831</fpage>
          <lpage>6</lpage>
          <volume>51</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Franciosa</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Wilen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ziesche</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Bart BA, Shaw    LK, McCants CB Jr, Fortin DF, Lee KL, Califf RM, et al. Clinical determinants    of mortality in patients with angiographically diagnosed ischemic or nonischemic    cardiomyopathy. J Am Coll Cardiol. 1997; 30: 1002-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>1002</fpage>
          <lpage>8</lpage>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bart</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>LK</given-names>
            </name>
            <name>
              <surname>McCants Jr</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Fortin</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Califf</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Volders PGA,    Willems IE, Cleutjens JP, Arends JW, Havenith MG, Daemen MJ. Interstitial collagen    is increased in the noninfarcted myocardium after myocardial infarction. J Mol    Cell Cardiol. 1993; 25: 1317-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Interstitial collagen is increased in the noninfarcted myocardium after myocardial infarction</article-title>
          <source>J Mol Cell Cardiol</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>1317</fpage>
          <lpage>23</lpage>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Volders</surname>
              <given-names>PGA</given-names>
            </name>
            <name>
              <surname>Willems</surname>
              <given-names>IE</given-names>
            </name>
            <name>
              <surname>Cleutjens</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Arends</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Havenith</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Daemen</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Wei S, Chow    LT, Schum IO, Chin L, Sanderson JE. . Left and right ventricular collagen type    I/III ratio and remodeling post-myocardial infarction. J Card Fail. 1999; 5:    117-26.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left and right ventricular collagen type I/III ratio and remodeling post-myocardial infarction</article-title>
          <source>J Card Fail</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>117</fpage>
          <lpage>26</lpage>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wei</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chow</surname>
              <given-names>LT</given-names>
            </name>
            <name>
              <surname>Schum</surname>
              <given-names>IO</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sanderson</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Cooper GIV.    Basic determinants of myocardial hypertrophy: a review of molecular mechanisms.    Annu Rev Med. 1997; 48: 13-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Basic determinants of myocardial hypertrophy: a review of molecular mechanisms</article-title>
          <source>Annu Rev Med</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>13</fpage>
          <lpage>23</lpage>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cooper</surname>
              <given-names>GIV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Iwai N, Shimoike    H, Kinoshita M. Genes up-regulated in hypertrophied ventricle. Biochem Biophys    Res Commun. 1995; 209: 527-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Genes up-regulated in hypertrophied ventricle</article-title>
          <source>Biochem Biophys Res Commun</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>527</fpage>
          <lpage>34</lpage>
          <volume>209</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Iwai</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Shimoike</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Kinoshita</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Beltrami CA,    Finato N, Rocco M, Feruglio GA, Puricelli C, C&#237;gola E, et al. Structural    basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation.    1994; 89: 151-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Structural basis of end-stage failure in ischemic cardiomyopathy in humans</article-title>
          <source>Circulation</source>
          <date>
            <year>1994</year>
          </date>
          <fpage>151</fpage>
          <lpage>63</lpage>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Beltrami</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Finato</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rocco</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Feruglio</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Puricelli</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>C&#237;gola</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Schaper J,    Froede R, Hein ST, Buck A, Hashizume H, Speiser B, et al. Impairment of the    myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy.    Circulation. 1991; 83: 504-14.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy</article-title>
          <source>Circulation</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>504</fpage>
          <lpage>14</lpage>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Schaper</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Froede</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hein</surname>
              <given-names>ST</given-names>
            </name>
            <name>
              <surname>Buck</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hashizume</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Speiser</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Weber KT, Brilla    CG. Pathological hypertrophy and cardiac interstitium. Circulation. 1991; 83:    1849-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pathological hypertrophy and cardiac interstitium</article-title>
          <source>Circulation</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>1849</fpage>
          <lpage>65</lpage>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Brilla</surname>
              <given-names>CG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Litwin SE,    Litwin CM, Raya TE, Warner AL, Goldman S. Contractility and stiffness of noninfarcted    myocardium after coronary ligation in rats: effects of chronic angiotensin converting    enzyme inhibition. Circulation. 1991; 83: 1028-37.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Contractility and stiffness of noninfarcted myocardium after coronary ligation in rats: effects of chronic angiotensin converting enzyme inhibition</article-title>
          <source>Circulation</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>1028</fpage>
          <lpage>37</lpage>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Litwin</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Litwin</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Raya</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Warner</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Goldman</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Hare JM, Walford    GD, Hruban RH, Hutchins GM, Deckers JW, Baughman KL. Ischemic cardiomyopathy:    endomyocardial biopsy and ventriculographic evaluation of patients with congestive    heart failure, dilated cardiomyopathy and coronary artery disease. J Am Coll    Cardiol. 1992; 20: 1318-25.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ischemic cardiomyopathy: endomyocardial biopsy and ventriculographic evaluation of patients with congestive heart failure, dilated cardiomyopathy and coronary artery disease</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>1318</fpage>
          <lpage>25</lpage>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hare</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Walford</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Hruban</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Hutchins</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Deckers</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Baughman</surname>
              <given-names>KL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Port SC. Imaging    guidelines for nuclear cardiology procedures. Part II. American Society of Nuclear    Cardiology. J Nucl Cardiol. 1999; 6: G47-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Imaging guidelines for nuclear cardiology procedures: Part II. American Society of Nuclear Cardiology</article-title>
          <source>J Nucl Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>G47</fpage>
          <lpage>84</lpage>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Port</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Berger HJ,    Gottschalk A, Zaret BL. First-pass radionuclide angiocardiography for evaluation    of right and left ventricular performance: computer applications and technical    considerations. In: Sorenson JA (ed). Nuclear cardiology: selected computer    aspects. New York: Society of Nuclear Medicine; 1978. p. 29-44.</mixed-citation>
        <element-citation publication-type="book">
          <source>Nuclear cardiology: selected computer aspects</source>
          <date>
            <year>1978</year>
          </date>
          <fpage>29</fpage>
          <lpage>44</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Berger</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Gottschalk</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zaret</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Sorenson</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19.Callahan RJ,    Froelich JW, Mckusick KA, Leppo J, Strauss HW. A modified method for the in    vivo labeling of red blood cells with Tc-99m: concise communication. J Nucl    Med. 1982; 23: 315-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A modified method for the in vivo labeling of red blood cells with Tc-99m: concise communication</article-title>
          <source>J Nucl Med</source>
          <date>
            <year>1982</year>
          </date>
          <fpage>315</fpage>
          <lpage>8</lpage>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Callahan</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Froelich</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Mckusick</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Leppo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Strauss</surname>
              <given-names>HW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Mason JW. Techniques    for right and left ventricular endomyocardial biopsy. Am J Cardiol. 1978; 41:    887-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Techniques for right and left ventricular endomyocardial biopsy</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1978</year>
          </date>
          <fpage>887</fpage>
          <lpage>92</lpage>
          <volume>41</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mason</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Brilla CG,    Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic    hypertension: role of interstitial fibrosis and medial thickening of intramyocardial    coronary arteries. Circ Res. 1991; 69: 107-15.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries</article-title>
          <source>Circ Res</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>107</fpage>
          <lpage>15</lpage>
          <volume>69</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brilla</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Janicki</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>KT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Brilla CG,    Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles    in experimental hypertension. Circ Res. 1990; 67: 1355-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Remodeling of the rat right and left ventricles in experimental hypertension</article-title>
          <source>Circ Res</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>1355</fpage>
          <lpage>64</lpage>
          <volume>67</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brilla</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Pick</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Janicki</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>KT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Doering CW,    Jalil JE, Janicki JS, Pick R, Aghili S, Abrahams C, et al. Collagen network    remodeling and diastolic stiffness of the rat left ventricle with pressure overload    hypertrophy. Cardiovasc Res. 1988; 22: 686-95.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Collagen network remodeling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy</article-title>
          <source>Cardiovasc Res</source>
          <date>
            <year>1988</year>
          </date>
          <fpage>686</fpage>
          <lpage>95</lpage>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Doering</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Jalil</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Janicki</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Pick</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Aghili</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Abrahams</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Brilla CG,    Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic    hypertension and left ventricular hypertrophy. Circulation. 1991; 83: 1771-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy</article-title>
          <source>Circulation</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>1771</fpage>
          <lpage>9</lpage>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brilla</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Janicki</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>KT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Pauschinger    M, Knopf D, Petschauer S, Doerner A, Poller W, Schwimmbeck PL, et al. Dilated    cardiomyopathy is associated with significant changes in collagen type I/III    ratio. Circulation. 1999; 99: 2750-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio</article-title>
          <source>Circulation</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>2750</fpage>
          <lpage>6</lpage>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pauschinger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Knopf</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Petschauer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Doerner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Poller</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schwimmbeck</surname>
              <given-names>PL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26.Mukherjee D,    Sen S. Alteration of collagen phenotypes in ischemic cardiomyopathy. J Clin    Invest. 1991; 88: 1141-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Alteration of collagen phenotypes in ischemic cardiomyopathy</article-title>
          <source>J Clin Invest</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>1141</fpage>
          <lpage>6</lpage>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mukherjee</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sen</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Weber KT, Anversa    P, Armstrong PW, Brilla CG, Burnett JC Jr, Cruickshank JM, et al. Remodeling    and reparation of the cardiovascular system. J Am Coll Cardiol. 1992; 20: 3-16.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Remodeling and reparation of the cardiovascular system</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>3</fpage>
          <lpage>16</lpage>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Anversa</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Brilla</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Burnett Jr</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Cruickshank</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28.Zisman LS,Asano    K,Dutcher DL, Ferdensi A, Robertson AD, Jenkin M, et al. Differential regulation    of cardiac angiotensin converting enzyme binding sites and AT1 receptor density    in the failing human heart. Circulation. 1998; 98: 1735-41.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1735</fpage>
          <lpage>41</lpage>
          <volume>98</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zisman</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Asano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dutcher</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Ferdensi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Robertson</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Jenkin</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29.Bishop JE, Greenbaum    R, Gibson DG, Yacoub M, Laurent GJ. Enhanced deposition of predominantly type    I collagen in myocardial disease. J Mol Cell Cardiol. 1990; 22: 1157-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Enhanced deposition of predominantly type I collagen in myocardial disease</article-title>
          <source>J Mol Cell Cardiol</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>1157</fpage>
          <lpage>65</lpage>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bishop</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Greenbaum</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Yacoub</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Laurent</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30.Brooks A, Schinde    V, Bateman AC, Gallagher PJ. Interstitial fibrosis in the dilated non-ischaemic    myocardium. Heart. 2003; 89: 1255-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Interstitial fibrosis in the dilated non-ischaemic myocardium</article-title>
          <source>Heart</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1255</fpage>
          <lpage>6</lpage>
          <volume>89</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brooks</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schinde</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bateman</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Gallagher</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31.Karsch KR, Kreuzer    H, Neuhaus KL. Myocardial function of the right ventricle in coronary disease.    Z Kardiol. 1976; 65 (11): 972-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial function of the right ventricle in coronary disease</article-title>
          <source>Z Kardiol</source>
          <date>
            <year>1976</year>
          </date>
          <fpage>972</fpage>
          <lpage>82</lpage>
          <issue>11</issue>
          <volume>65</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Karsch</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Kreuzer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Neuhaus</surname>
              <given-names>KL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32.La Vecchia L,    Luca Spadaro G, Paccanaro M, Favero L, Zanolla L, Vincenzi P, et al. Predictors    of right ventricular dysfunction in patients with coronary artery disease and    reduced left ventricular ejection fraction. Coron Artery Dis. 2002; 13 (6):    319-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Predictors of right ventricular dysfunction in patients with coronary artery disease and reduced left ventricular ejection fraction</article-title>
          <source>Coron Artery Dis</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>319</fpage>
          <lpage>22</lpage>
          <issue>6</issue>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>La Vecchia</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Luca Spadaro</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Paccanaro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Favero</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zanolla</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vincenzi</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Hess OM, Schneider    J, Koch R, Bamert C, Crimm J, Krayenbuehl HP. Diastolic function and myocardial    structure in patients with myocardial hypertrophy: special reference to normalized    viscoelastic data. Circulation. 1981; 63: 360-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diastolic function and myocardial structure in patients with myocardial hypertrophy: special reference to normalized viscoelastic data</article-title>
          <source>Circulation</source>
          <date>
            <year>1981</year>
          </date>
          <fpage>360</fpage>
          <lpage>71</lpage>
          <volume>63</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hess</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bamert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Crimm</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Krayenbuehl</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Pelouch V,    Dixon IMC, Golfman L, Beamish RE, Dhalla NS. Role of extracellular matrix proteins    in heart function. Mol Cell Biochem. 1993; 129: 101-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Role of extracellular matrix proteins in heart function</article-title>
          <source>Mol Cell Biochem</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>101</fpage>
          <lpage>20</lpage>
          <volume>129</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pelouch</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Dixon</surname>
              <given-names>IMC</given-names>
            </name>
            <name>
              <surname>Golfman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Beamish</surname>
              <given-names>RE</given-names>
            </name>
            <name>
              <surname>Dhalla</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Smits JFM,    Van Krimpen C, Schoemaker RG, Cleutjens JP, Daemen MJ. Angiotensin II receptor    blockade after myocardial infarction in rats: effects on hemodynamics, myocardial    DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol. 1992;    20: 772-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content</article-title>
          <source>J Cardiovasc Pharmacol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>772</fpage>
          <lpage>8</lpage>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Smits</surname>
              <given-names>JFM</given-names>
            </name>
            <name>
              <surname>Van Krimpen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schoemaker</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Cleutjens</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Daemen</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Pfeffer JM,    Pfeffer MA, Fishbein MC, Frohlich ED. Cardiac function and morphology with aging    in the spontaneously hypertensive rat. Am J Physiol. 1979; 6: H461-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac function and morphology with aging in the spontaneously hypertensive rat</article-title>
          <source>Am J Physiol</source>
          <date>
            <year>1979</year>
          </date>
          <fpage>H461</fpage>
          <lpage>8</lpage>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pfeffer</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Fishbein</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Frohlich</surname>
              <given-names>ED</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Klappacher    G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, et al. Measuring extracellular    matrix turnover in the serum of patients with idiopathic or ischemic dilated    cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995; 175    (14): 913-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>913</fpage>
          <lpage>8</lpage>
          <issue>14</issue>
          <volume>175</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Klappacher</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Franzen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Haab</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mehrabi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Binder</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Plesch</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Brilla CG,    Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients    with hypertensive heart disease. Circulation. 2000; 102: 1388-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease</article-title>
          <source>Circulation</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1388</fpage>
          <lpage>93</lpage>
          <volume>102</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Brilla</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Funck</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Rupp</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Dahlof B, Pennert    K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients:    a metanalysis of 109 treatment studies. Am J Hypertens. 1992; 5: 95-110.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Reversal of left ventricular hypertrophy in hypertensive patients: a metanalysis of 109 treatment studies</article-title>
          <source>Am J Hypertens</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>95</fpage>
          <lpage>110</lpage>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dahlof</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pennert</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hansson</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Diez R, Querejeta    R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression    of myocardial fibrosis is associated with reduction of left-ventricular chamber    stiffness in hypertensive patients. Circulation. 2002; 105: 2512-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Losartan-dependent regression of myocardial fibrosis is associated with reduction of left-ventricular chamber stiffness in hypertensive patients</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>2512</fpage>
          <lpage>7</lpage>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Diez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Querejeta</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lopez</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Larman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Martinez Ubago</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B41">
        <mixed-citation>41. Marijianowski    MMH, Teeling P, Becker A. Remodeling after myocardial infarction in humans is    not associated with intersticial fibrosis of noninfarcted myocardium. J Am Coll    Cardiol. 1997; 30: 76-82.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Remodeling after myocardial infarction in humans is not associated with intersticial fibrosis of noninfarcted myocardium</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>76</fpage>
          <lpage>82</lpage>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Marijianowski</surname>
              <given-names>MMH</given-names>
            </name>
            <name>
              <surname>Teeling</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B42">
        <mixed-citation>42. Volders PGA,    Daemen MJAP. Interstitial fibrosis and angiotensin-converting enzyme inhibition    in patients with end-stage myocardial infarction. (letter). J Am Coll Cardiol.    1998; 32: 552.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Interstitial fibrosis and angiotensin-converting enzyme inhibition in patients with end-stage myocardial infarction. (letter)</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>552</fpage>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Volders</surname>
              <given-names>PGA</given-names>
            </name>
            <name>
              <surname>Daemen</surname>
              <given-names>MJAP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B43">
        <mixed-citation>43. Pfeffer MA,    Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril    on mortality and morbidity in patients with left ventricular dysfunction after    myocardial infarction: results of the Survival and Ventricular Enlargement Trial.    N Engl J Med. 1992; 327: 669-77.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>669</fpage>
          <lpage>77</lpage>
          <volume>327</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pfeffer</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Moye</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Basta</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Brown Jr</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Cuddy</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <mixed-citation>44. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left-ventricular ejection fractions: the SOLVD Investigators. N Engl J Med. 1992; 327: 685-91.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left-ventricular ejection fractions: the SOLVD Investigators</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>685</fpage>
          <lpage>91</lpage>
          <volume>327</volume>
        </element-citation>
      </ref>
      <ref id="B45">
        <mixed-citation>45. Pitt B, Zanna    F, Remm WJ, Cody R, Castaigne A, Perez A, et al. for The Randomized Aldactone    Evaluation Study Investigators. The effect of spironolactone on morbidity and    mortality in patients with severe heart failure. N Engl J Med. 1999; 341: 709-17.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The effect of spironolactone on morbidity and mortality in patients with severe heart failure</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>709</fpage>
          <lpage>17</lpage>
          <volume>341</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pitt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Zanna</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Remm</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Cody</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Castaigne</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B46">
        <mixed-citation>46. Pitt B, Remme    W, Zannad F, Neaton J, Martinez F, Roniker B, et al. The Eplerenone Post-Acute    Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators.    Eplerenone, a selective aldosterona blocker in patients with left ventricular    dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterona blocker in patients with left ventricular dysfunction after myocardial infarction</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1309</fpage>
          <lpage>21</lpage>
          <volume>348</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pitt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Remme</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Zannad</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Neaton</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Roniker</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B47">
        <mixed-citation>47. Hayashi M,    Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, et al. Immediate administration    of mineralocorticoid receptor antagonist spironolactone prevents postinfarct    left ventricular remodeling associated with suppression of a marker of myocardial    collagen synthesis in patients with first anterior acute myocardial infarction.    Circulation. 2003; 107: 2559-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents postinfarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>2559</fpage>
          <lpage>65</lpage>
          <volume>107</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hayashi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tsutamoto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wada</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tsutsui</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ohno</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B48">
        <mixed-citation>48. Pickering JG,    Boughner DR. Fibrosis in the transplanted heart and its relation to donor ischemic    time. Circulation. 1990; 80: 949-58.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Fibrosis in the transplanted heart and its relation to donor ischemic time</article-title>
          <source>Circulation</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>949</fpage>
          <lpage>58</lpage>
          <volume>80</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pickering</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Boughner</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B49">
        <mixed-citation>49. Chello M, Mastroroberto    P, Romano R, Perticone F, Marchese AR. Collagen network remodeling and left    ventricular function in constrictive pericarditis. Heart. 1996; 75: 184-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Collagen network remodeling and left ventricular function in constrictive pericarditis</article-title>
          <source>Heart</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>184</fpage>
          <lpage>9</lpage>
          <volume>75</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chello</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mastroroberto</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Perticone</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Marchese</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Correlation of myocardial interstitial collagen in the right ventricular septum with ventricular function of patients with ischemic cardiomyopathy</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Myocardial collagen content influences ventricular relaxation, contraction, and morphology. Its relationship with ventricular function in patients (Pts) with ischemic cardiomyopathy (ICMP) has not yet been fully studied in humans. OBJECTIVE: To assess the relationship between interstitial collagen content in non-infarcted areas of the right ventricular septum and ventricular function in ICMP. METHODS: 31 pts with coronary artery disease were divided into four groups as follows:The control group consisted of 7 pts with normal left (LVEF) and right (RVEF) ventricular ejection fraction (group C); Group 1: 5 patients with RVEF &lt; 40%; Group 2: 9 pts with LVEF &lt; 40%; and Group 3, 10 pts with biventricular dysfunction. RVEF and LVEF were measured by radionuclide angiography. For quantitative analysis of interstitial collagen volume fraction (CVF), endomyocardial biopsy specimens were taken from the right ventricle and stained with picrosirius red. RESULTS: Mean CVF was significantly higher in group 3, compared with the control group and with groups 1 and 2 (30.2 &#177; 7.9% vs. 6.8 &#177; 3.3% vs. 15.8 &#177; 4.1% vs. 17.5&#177;7.7%, respectively; p =0.0001). It was also significantly higher in patients belonging to group 2, compared with those in the control group (17.5 &#177; 7.7% vs. 6.8 &#177; 3.3%, p =0.0001). CVF was inversely correlated with RVEF (r = - 0.50, p = 0.003) and LVEF (r = -0.70, p = 0.0001). CONCLUSION: In ICMP, CVF is elevated in non-infarcted areas of the right ventricular septum and inversely correlated with right and left ventricular function.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Myocardial ischemia</kwd>
        <kwd>cardiac output, low</kwd>
        <kwd>ventricular function, right</kwd>
        <kwd>ventricular function, left</kwd>
        <kwd>collagen</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Correlation of myocardial interstitial collagen in the right ventricular septum with ventricular function of patients with ischemic cardiomyopathy</bold>
          </label>
          <p>
            <bold>Marcelo Westerlund Montera<sup>I,</sup><sup>II,</sup><sup>III</sup>; Cant&#237;dio Drumond<sup>V</sup>; Cristina Takiya<sup>VI</sup>; Cl&#225;udio Tinoco Mesquita<sup>III</sup>; Hans Fernando R. Dohmann<sup>IV</sup>, Charles Mady<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Universidade de S&#227;o Paulo, Instituto do Cora&#231;&#227;o (InCor), S&#227;o Paulo, SP Hospital Pr&#243;-Card&#237;aco</p>
      <p><sup>II</sup>Centro de Insufici&#234;ncia Card&#237;aca -</p>
      <p><sup>III</sup>Laborat&#243;rio de Medicina Nuclear</p>
      <p><sup>IV</sup>Laborat&#243;rio de Cateterismo Card&#237;aco, Rio de Janeiro, RJ; Santa Casa de Miseric&#243;rdia -</p>
      <p><sup>V</sup>Departamento de Cardiologia, Rio de Janeiro, RJ, Universidade Federal do Rio de Janeiro -</p>
      <p><sup>VI</sup>Departamento de Histologia, Rio de Janeiro, RJ - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND: </bold> Myocardial collagen content influences ventricular relaxation, contraction, and morphology. Its relationship with ventricular function in patients (Pts) with ischemic cardiomyopathy (ICMP) has not yet been fully studied in humans.</p>
      <p><bold>OBJECTIVE: </bold> To assess the relationship between interstitial collagen content in non-infarcted areas of the right ventricular septum and ventricular function in ICMP.</p>
      <p><bold>METHODS: </bold> 31 pts with coronary artery disease were divided into four groups as follows:The control group consisted of 7 pts with normal left (LVEF) and right (RVEF) ventricular ejection fraction (group C); Group 1: 5 patients with RVEF &lt; 40%; Group 2: 9 pts with LVEF &lt; 40%; and Group 3, 10 pts with biventricular dysfunction. RVEF and LVEF were measured by radionuclide angiography. For quantitative analysis of interstitial collagen volume fraction (CVF), endomyocardial biopsy specimens were taken from the right ventricle and stained with picrosirius red.</p>
      <p><bold>RESULTS: </bold> Mean CVF was significantly higher in group 3, compared with the control group and with groups 1 and 2 (30.2 &#177; 7.9% vs. 6.8 &#177; 3.3% vs. 15.8 &#177; 4.1% vs. 17.5&#177;7.7%, respectively; p =0.0001). It was also significantly higher in patients belonging to group 2, compared with those in the control group (17.5 &#177; 7.7% vs. 6.8 &#177; 3.3%, p =0.0001). CVF was inversely correlated with RVEF (r = - 0.50, p = 0.003) and LVEF (r = -0.70, p = 0.0001).</p>
      <p><bold>CONCLUSION: </bold> In ICMP, CVF is elevated in non-infarcted areas of the right ventricular septum and inversely correlated with right and left ventricular function.</p>
      <p><bold>Key words:</bold> Myocardial ischemia; cardiac output, low; ventricular function, right; ventricular function, left; collagen.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Heart failure (HF) is a highly prevalent syndrome that affects approximately 1% to 1.5% of the adult population. It is estimated that 4.7 million people in the United States have heart failure, with 400,000 new cases being diagnosed every year<sup>1-3</sup>. The majority of cases result from heart muscle diseases, known as cardiomyopathies, of which ischemic cardiomyopathy (ICM) is the most common, accounting for 40% to 80% of all cardiomyopathies<sup>1,4</sup>. Ischemic cardiomyopathy carries a worse prognosis than idiopathic dilated cardiomyopathy<sup>4-7</sup>, probably due to the presence of areas of myocardial ischemia and fibrosis from prior infarction, which may predispose to arrhythmias and extensive ventricular remodeling.</p>
      <p>The activation of ventricular remodeling is related to the extent of myocardial necrosis, fibrosis, and ischemia in the infarcted area. However, it has been demonstrated that morphological changes in the remote non-infarcted myocardium play a major role in the development of ventricular remodeling<sup>8,9</sup>. These include diffuse perivascular fibrosis, interstitial fibrosis, and diffuse atrophy of cardiac myocytes<sup>10</sup>. Changes in myocardial matrix at sites distant from myocardial scarring account for approximately two-thirds of all cardiac fibrous tissue and are regarded as the primary component of ventricular remodeling in ischemic cardiomyopathy<sup>11,12</sup>.</p>
      <p>The morphological and morphometric changes that occur in the myocardium following myocardial infarction, with the development of left ventricular (LV) systolic and diastolic dysfunctions, are well described in the literature<sup>8,13-16</sup>. However, the relationship between these changes in the extracellular matrix of the non-infarcted myocardium and right (RV) and left (LV) ventricular systolic function in ICM is not well-established.</p>
      <p>The aim of this study is to assess the relationship between interstitial collagen content, measured by right ventricular septal biopsy, and right and left ventricular systolic function in ICM patients with varying degrees of ventricular dysfunction.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>From January to December 2003, thirty-one patients with angiographically documented coronary artery disease were consecutively included in the study for diagnostic evaluation of precordial pain or left ventricular dysfunction. They were divided into four groups according to left (LVEF) and right (RVEF) ventricular ejection fractions measured by radionuclide angiography as follows: Control group (Group C), seven patients with preserved LV and RV systolic function; Group 1, five patients with isolated RV systolic dysfunction (RVEF &lt; 40%); Group 2, nine patients with isolated LV systolic dysfunction (LVEF &lt; 40%); and Group 3, ten patients with right and left ventricular systolic dysfunction. Patients with pulmonary hypertension, chronic obstructive pulmonary disease (COPD), infiltrative or restrictive myocardial diseases, and collagen diseases were excluded from the study, as were those with suspected myocarditis, myocardial infarction with septal involvement or right ventricular dysfunction secondary to right ventricular cardiomyopathy. The study protocol was approved by the Institutional Ethics Committee, and an informed consent was obtained from all patients.</p>
      <p>All patients underwent biochemical tests, including renal function tests, electrocardiography (ECG), and transthoracic echocardiography (ECHO). Exclusion criteria were septal myocardial infarction on ECG and ECHO, significant valvular heart disease, systemic hypertension (blood pressure &gt; 140x90 mmHg), serum creatinine above 1.4 mg/dL, atrial fibrillation, clinical instability of less than two weeks, and chronic obstructive pulmonary disease.</p>
      <p>
        <bold>Cardiac catheterization</bold>
      </p>
      <p>All patients underwent coronary angiography via the femoral approach using Sones' technique. Coronary artery disease was defined as stenosis greater than 50% in at least one major epicardial coronary artery. Ventriculography was also performed in all subjects.</p>
      <p>
        <bold>Analysis of ventricular function</bold>
      </p>
      <p>Both right and left ventricular functions were assessed by equilibrium and first-pass radionuclide angiography. Left and right ventricular ejection fractions were calculated using the standard method recommended by the American Society of Nuclear Cardiology<sup>17</sup>, with the lower limit of normal set at 40% for both ventricles. Right ventricular ejection fraction (RVEF) was measured by first-pass radionuclide angiography using a DIACAM Siemens gamma camera connected to an ICON computer. The study protocol was validated by the Cardiovascular Nuclear Imaging Laboratory of the Yale University School of Medicine<sup>18</sup>. Tc-99m was injected at rest in all patients to assess ventricular function. Images were acquired in the supine position, with the detector in the right anterior oblique (RAO) projection (20&#176; to 30&#176;). First-pass images were analyzed independently by two nuclear medicine physicians, using two regions of interest. Mean values for right and left ventricular functions were used for statistical analysis. Beats with end-diastolic counts below 50% of the maximum end-diastolic count were excluded, as were premature ventricular beats and post-premature ventricular contraction (PVC) beats. For statistical analysis purposes, normal right ventricular ejection fraction was considered to be equal to or greater than 40%.</p>
      <p>LVEF was measured by planar equilibrium radionuclide angiography with the modified technique for <italic>in-vivo</italic> labeling, using 2 to 3 mg of stannous pyrophosphate 15 minutes before injecting 20 mCi of Tc-99m-pertechnetate<sup>19</sup>. Images were acquired in the supine position with the detector in the left anterior oblique (LAO) projection at 45 degrees. Left ventricular systolic dysfunction was defined as LVEF d" 40%.</p>
      <p>
        <bold>Endomyocardial biopsy</bold>
      </p>
      <p>Right ventricular endomyocardial biopsies were performed percutaneously according to Mason's technique<sup>20</sup> using a Cordis bioptome, and four tissue samples were obtained from the interventricular septum of each patient.</p>
      <p>
        <bold>Histological study and quantification of interstitial collagen</bold>
      </p>
      <p>Biopsy specimens were fixed in 10% buffered formalin and embedded in paraffin. Serial, 5-&#188;m-thick sections were mounted on glass slides and stained with hematoxylin-eosin, Masson's trichrome, and Sirius Red (0.1% Sirius red F3BA dissolved in saturated picric acid, pH 2.0). Ten fields per section were analyzed at a magnification of x320. Collagen content was measured by quantitative morphometric analysis of sirus-red-stained sections, with an automatic image analyzer (Image-Pro Plus 4.5.1 software, Media Cybernetics, Silver Spring, MD, USA). Images were captured using a Coolpix 900 digital camera attached to an Eclipse E400 light microscope (both manufactured by Nikon, Japan). Each histological section was viewed at a magnification of x40. Collagen fibers were stained blue under direct light, and images were digitized. Interstitial collagen volume fraction (CVF) in each field was calculated as the sum of all connective tissue area divided by the sum of all connective tissue and cardiac myocyte areas, as demonstrated previously in a number of studies<sup>21-24</sup>.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Quantitative data among the four groups were compared by Kruskal-Wallis analysis of variance. The Kruskal-Wallis test for multiple comparisons was applied as a complementary method to ANOVA, since some variables were not normally distributed (Gaussian distribution). Given the small number of cases, Fisher's exact test was used to compare proportions between groups (qualitative data). The Mann-Whitney test was used to compare means, and the Spearman correlation coefficient, to assess the correlation between collagen fraction and numerical variables. A receiver operating characteristic (ROC) curve was constructed to determine the best cut-off point for CVF to predict right and left ventricular dysfunction. The significance level was set at 5%. Statistical analyses were performed using SAS<sup>&#174;</sup> statistical software.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>Patients' characteristics</p>
      <p>Clinical characteristics of the patients are summarized in <xref ref-type="table" rid="en_09t1-body2">Table I</xref>. No significant difference was found in clinical and demographic variables among the four groups, except for lower incidence of smoking in group 3. Most patients were on angiotensin-converting enzyme inhibitors and beta-blockers, with no significant differences among groups regarding drug regimen.</p>
      <p content-type="asset">
        <table-wrap id="en_09t1-body2">
          <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gt01-en.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Coronary artery disease</bold>
      </p>
      <p>The majority of patients (84%) had two- or three-vessel disease, the left anterior descending artery (LAD) being the most frequently affected. There was no difference among the four groups with regard to the presence of lesions involving the proximal left anterior descending and right coronary (RC) arteries (p = 0.91) <xref ref-type="table" rid="en_09t2-body2">Table 2</xref>.</p>
      <p content-type="asset">
        <table-wrap id="en_09t2-body2">
          <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gt02-en.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Analysis of ventricular function</bold>
      </p>
      <p>Mean LVEF was 51.5 &#177; 8.5 in the control group and 50.6 &#177; 8.8, 27.9 &#177; 5,1, and 21.7 &#177; 4.7% in groups 1, 2, and 3, respectively. Mean RVEF in the four groups were, respectively, 42.4 &#177; 4.7, 28.2 &#177; 2.7, 50.3 &#177; 5.1, and 22.0 &#177; 6.5%. No significant difference was found in LVEF between groups with biventricular dysfunction and isolated left ventricular dysfunction (21.7 &#177; 4.7% <italic>vs.</italic> 27.9 &#177; 5.1, p = 0.10). This was also true for RVEF between groups with biventricular dysfunction and isolated left ventricular dysfunction (28.2 &#177; 2.7 <italic>vs.</italic> 22.0 &#177; 6.5%, p = 0.10).</p>
      <p>
        <bold>Analysis of collagen volume fraction</bold>
      </p>
      <p>Mean collagen volume fraction (CVF) is shown in <xref ref-type="fig" rid="fig1-body2">figure 1</xref>. Collagen content was higher in the group with biventricular dysfunction, compared with the control group and groups with isolated right or left ventricular dysfunction (30.2 &#177; 7.9 <italic>vs.</italic> 6.8 &#177; 3.3, 15.8 &#177; 4.1, and 17.5 &#177; 7.7%, respectively; <italic>p</italic> = 0.0001). Patients with isolated left ventricular dysfunction had higher CVF than the control group (17.5 &#177; 7.7 <italic>vs.</italic> 6.8 &#177; 3.3%, <italic>p</italic> = 0.0001). The group with isolated right ventricular dysfunction showed a tendency to higher CVF, compared with the control group (15.8 &#177; 4.1 <italic>vs.</italic> 6.8 &#177; 3.3, <italic>p</italic> = 0.08) (<xref ref-type="fig" rid="fig2-body2">Figure 2</xref>).</p>
      <fig id="fig1-body2">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf01-en.jpg"/></fig>
      <fig id="fig2-body2">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf02-en.jpg"/></fig>
      <p>
        <bold>Correlation between collagen volume fraction and ventricular function</bold>
      </p>
      <p>There was a significant inverse linear relationship between collagen fraction and RVEF (<italic>r</italic> = -0.50; <italic>p</italic> = 0.003, n = 31) and LVEF (<italic>r</italic> = -0.70; <italic>p</italic> = 0.0001, n = 27), demonstrating that the higher the collagen fraction the lower the RVEF and LVEF, as shown in <xref ref-type="fig" rid="fig3-body2">Figures 3</xref> and <xref ref-type="fig" rid="fig4-body2">4</xref>.</p>
      <fig id="fig3-body2">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf03-en.jpg"/></fig>
      <fig id="fig4-body2">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf04-en.jpg"/></fig>
      <p>
        <bold>ROC curve analysis</bold>
      </p>
      <p>The best cut-off point for CVF for the association with LVEF <underline>&lt;</underline>40% was 18.3%, with sensitivity of 70.5%, specificity of 90%, and area under the ROC curve of 0.87 (95% CI: 0.7- 0.9; <italic>p</italic> = 0.0001) (<xref ref-type="fig" rid="en_09f5-body2">Figure 5 a</xref>). For the association with RVEF d" 40%, the cut-off point was 12.9%, with sensitivity of 82%, specificity of 64.2%, and area under the ROC curve of 0.77 (CI 95%: 0.59-0.9; <italic>p</italic> = 0.0001) (<xref ref-type="fig" rid="en_09f5-body2">Figure 5 b</xref>).</p>
      <p content-type="asset">
        <fig id="en_09f5-body2">
          <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf05-en.jpg"/></fig>
      </p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>This is the first human study published in the literature to demonstrate a direct relationship between interstitial collagen content in the right ventricle and right and left ventricular dysfunction in patients with ischemic cardiomyopathy. A linear correlation was observed between CVF in the non-infarcted myocardium and the degree of right and left ventricular dysfunction. Interstitial collagen fraction was 4.4 times higher in patients with biventricular dysfunction, 2.5 times higher in patients with isolated left ventricular dysfunction, and 2.3 times higher in patients with isolated right ventricular dysfunction, as compared with those with preserved ventricular function, showing an inverse correlation between collagen content and LVEF and RVEF. The association between ventricular dysfunction and the degree of interstitial collagen proliferation was reinforced by the demonstration of an inverse linear correlation between collagen content and RVEF and LVEF (<xref ref-type="fig" rid="fig3-body2">Figures 3</xref> and <xref ref-type="fig" rid="fig4-body2">4</xref>). The analysis of the relationship between several volume fractions of interstitial collagen and ventricular function allowed us to establish a cut-off point of 12.9% and 18%, respectively, for the prognosis of right ventricular dysfunction and left ventricular dysfunction, with high sensitivity (82.0% and 70.5%, respectively) and specificity (64.2% and 90.0%, respectively), and areas under the ROC curve of 0.87 and 0.77, respectively, indicating that these cut-off points are strongly correlated with CVF for discriminating the presence of ventricular dysfunction (<xref ref-type="fig" rid="en_09f5-body2">Figures 5 a</xref> and <xref ref-type="fig" rid="en_09f5-body2">b</xref>).</p>
      <p>Studies in human and animal models have demonstrated that changes in myocardial collagen network in ischemic and non-ischemic cardiomyopathy play a major role in the development of ventricular dysfunction. Particularly, the possibility was raised that collagen deposition within the cardiac interstitium may be a primary factor contributing to, rather than only a marker of, the development of myocardial dysfunction<sup>8,9,12-16,25,26</sup>. This has been emphasized in studies demonstrating that post-myocardial infarction remodeling is associated with increased interstitial fibrosis in the non-infarcted myocardium, which is correlated with progressive myocardial stiffness and thus to systolic and diastolic dysfunction<sup>12,13,26-28</sup>. Also supporting our findings of greater proliferation of interstitial collagen in biventricular dysfunction is the evidence of increased production of angiotensin in the myocardium of patients with right ventricular dysfunction secondary to pulmonary hypertension<sup>29</sup>.</p>
      <p>The difficulty in confirming the association between the degree of right or left ventricular dysfunction and interstitial collagen content lies in the lack of human <italic>in vivo</italic> studies analyzing collagen and the degree of ventricular dysfunction, particularly right ventricular dysfunction. This may be partly due to a failure of current methods to accurately assess right ventricular systolic and diastolic function.</p>
      <p>Pauschinger et al<sup>25</sup> have found that interstitial collagen was increased in patients with dilated cardiomyopathy and LVEF &lt; 50%, compared with those with LVEF &gt; 50% (4.3 &#177; 0.1% <italic>vs.</italic> 2.7 &#177; 0.9 %, <italic>p</italic> &lt; 0.0035), in addition to increased collagen type I/III ratio.</p>
      <p>Interstitial collagen content is also increased in non-ischemic dilated cardiomyopathy<sup>30</sup>, but to a lesser extent than in ischemic cardiomyopathy<sup>12,13</sup>. This increased collagen content in ischemic cardiomyopathy results not only from ventricular remodeling induced by myocardial infarction, but also from the trophic stimulation of myocardial ischemia<sup>31,32</sup>. An excessive amount of interstitial collagen leads to myocardial fibrosis and, consequently, myocardial stiffness and diastolic dysfunction, in addition to subsequent impairment of systolic function<sup>8,33-36</sup>. Weber and Brilla<sup>14</sup> suggest that deposition of interstitial collagen is the primary determinant of impaired ventricular relaxation. Collagen accumulation is also related to the clinical severity of heart failure, the degree of hemodynamic impairment, hyponatremia, and need for heart transplantation<sup>37</sup>. In contrast, hypertensive patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have shown a reduction in myocardial fibrosis and ventricular hypertrophy, regardless of the decrease in blood pressure, with improvement in systolic and diastolic ventricular function, cardiac arrhythmias, and clinical symptoms, as well as reduced ventricular mass<sup>38-40</sup> .</p>
      <p>This strongly suggests that increased interstitial collagen in ischemic cardiomyopathy is a major determinant of ventricular dysfunction, and not only a marker of the degree of ventricular remodeling. In patients with ischemic cardiomyopathy, collagen content was found to be increased not only in the infarcted, but specially in the non-infarcted myocardium<sup>8,12,16</sup>, a finding that was challenged by Marijianowski <italic>et al</italic><sup>41</sup> but corroborated by others<sup>37,42</sup>.</p>
      <p>Our findings have important implications for clinical practice, since they demonstrate that, in less severe forms of ventricular dysfunction, there is a significant increase in collagen content and that its progression is directly related to worsening ventricular dysfunction and the degree of ventricular remodeling. They also suggest that in less advanced phases of ventricular dysfunction, the inhibition of collagen production with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists may contribute to reduce both the progression of ventricular remodeling and mortality, as was demonstrated in advanced ventricular dysfunction<sup>43-47</sup>.</p>
      <p>
        <bold>Study limitations</bold>
      </p>
      <p>Some limitations of our study should be noted. Most patients were using ACE inhibitors, which may have affected collagen content, since these agents can reduce myocardial fibrosis. However, no difference was found between groups regarding the use of these medications and their dosage. Another limitation was that only endomyocardial biopsies from the right ventricular septum were used, restricting our study to a single ventricular region, without an analysis of the regional distribution of collagen content. Yet, only in explanted hearts with end-stage heart failure would such analysis be possible, and this was beyond the scope of this study. Another limiting factor was the lack of a control group, that is, patients without coronary disease who underwent endomyocardial biopsy, which was not feasible due to ethical reasons. However, mean collagen content in the group with preserved ventricular function was similar to that found in studies of patients without coronary artery disease that used endomyocardial biopsies taken from the RV septum<sup>48</sup> and LV free wall<sup>49</sup>. An analysis of collagen type I/III ratio would have provided information on the potential reversibility of myocardial fibrosis and enhancement of ventricular function, as suggested by Pauschinger et al<sup>25</sup>. Finally, the presence of myocardial ischemia, which might have influenced the degree of collagen content, was not evaluated in our study, although the extent of coronary artery disease, as documented by coronary angiography, was found to be similar among groups.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>Concluding, in patients with ischemic cardiomyopathy, there is an increase in collagen content in the non-infarcted region of the right ventricular septum, which is inversely correlated to the degree of right and left ventricular systolic dysfunction.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This article is part of the thesis of Doctoral submitted by Marcelo Westerlund Montera, from Universidade de S&#227;o Paulo.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Art&#237;culos Originales</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="es">Correlaci&#243;n del col&#225;geno intersticial mioc&#225;rdico del septo del ventr&#237;culo derecho con la funci&#243;n ventricular en pacientes con cardiomiopat&#237;a isqu&#233;mica</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: El contenido de col&#225;geno intersticial (CI) en el miocardio ejerce influencia en la relajaci&#243;n y en la contracci&#243;n ventricular. Su relaci&#243;n con la funci&#243;n ventricular en pacientes (pcts) con cardiomiopat&#237;a isqu&#233;mica (CMPI) no est&#225; plenamente estudiada en humanos. OBJETIVO: Evaluar la relaci&#243;n de la cantidad de CI en las &#225;reas no infartadas en el septo del ventr&#237;culo derecho con la funci&#243;n ventricular en la CMPI. M&#201;TODOS: Se clasificaron a 31 pcts con enfermedad arterial coronaria en cuatro grupos: Grupo C (Control): 7 pcts con fracci&#243;n de eyecci&#243;n de los ventr&#237;culos izquierdo (FEVI) y derecho (FEVD) normales; Grupo 1:5 pcts con FEVD &lt; 40%; Grupo 2:9 pcts con FEVI &lt; 40%; Grupo 3:10 pcts con disfunci&#243;n de ambos los ventr&#237;culos. La FEVD y la FEVI se calcularon por medio de la angiocardiograf&#237;a con radion&#250;clidos. Las muestras para an&#225;lisis del porcentaje de col&#225;geno intersticial (%CI) se obtuvieron mediante biopsia endomioc&#225;rdica del ventr&#237;culo derecho y se colorearon con la t&#233;cnica del picrosirius red. RESULTADOS: El promedio del %CI fue significativamente mayor en el grupo 3 cuando comparado al grupo-c y a los grupos 1 y 2 (30,2 &#177; 7,9% vs. 6,8 &#177; 3,3% vs. 15,8 &#177; 4,1% vs. 17,5 &#177; 7,7%, respectivamente; p = 0,0001). El %CI fue asimismo significativamente mayor en los pacientes del grupo 2 cuando comparado al control (17,5 &#177; 7,7% vs. 6,8 &#177; 3,3%, p = 0.0001). El %CI present&#243; correlaci&#243;n inversa con la FEVD (r = -0,50, p = 0.003) y la FEVI (r = -0,70, p = 0,0001). CONCLUSI&#211;N: En la CMPI, el %CI se encuentra elevado en las &#225;reas no infartadas en el septo del ventr&#237;culo derecho y presenta correlaci&#243;n inversa con la funci&#243;n ventricular derecha e izquierda.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Isquemia mioc&#225;rdica</kwd>
        <kwd>bajo d&#233;bito card&#237;aco</kwd>
        <kwd>funci&#243;n ventricular derecha</kwd>
        <kwd>funci&#243;n ventricular izquierda</kwd>
        <kwd>col&#225;geno</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Correlaci&#243;n del col&#225;geno intersticial mioc&#225;rdico del septo del ventr&#237;culo derecho con la funci&#243;n ventricular en pacientes con cardiomiopat&#237;a isqu&#233;mica</bold>
          </label>
          <p>
            <bold>Marcelo Westerlund Montera<sup>I, II, III</sup>; Cant&#237;dio Drumond<sup>V</sup>; Cristina Takiya<sup>VI</sup>; Cl&#225;udio Tinoco Mesquita<sup>III</sup>; Hans Fernando R. Dohmann<sup>IV</sup>; Charles Mady<sup>I</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Universidad de S&#227;o Paulo, Instituto do Cora&#231;&#227;o (InCor), S&#227;o Paulo, SP- Brasil</p>
      <p><sup>II</sup>Hospital Pr&#243;-Card&#237;aco - Centro de Insuficiencia Card&#237;aca- Brasil</p>
      <p><sup>III</sup>Laboratorio de Medicina Nuclear- Brasil</p>
      <p><sup>IV</sup>Laboratorio de Cateterismo Card&#237;aco- Brasil</p>
      <p><sup>V</sup>Rio de Janeiro, RJ; Santa Casa de Misericordia - Departamento de Cardiolog&#237;a, Rio de Janeiro, RJ- Brasil</p>
      <p><sup>VI</sup>Universidad Federal del Rio de Janeiro - Departamento de Histolog&#237;a, Rio de Janeiro, RJ - Brasil</p>
      <p>Correspond&#234;ncia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> El contenido de col&#225;geno intersticial (CI) en el miocardio ejerce influencia en la relajaci&#243;n y en la contracci&#243;n ventricular. Su relaci&#243;n con la funci&#243;n ventricular en pacientes (pcts) con cardiomiopat&#237;a isqu&#233;mica (CMPI) no est&#225; plenamente estudiada en humanos.</p>
      <p><bold>OBJETIVO:</bold> Evaluar la relaci&#243;n de la cantidad de CI en las &#225;reas no infartadas en el septo del ventr&#237;culo derecho con la funci&#243;n ventricular en la CMPI.</p>
      <p><bold>M&#201;TODOS:</bold> Se clasificaron a 31 pcts con enfermedad arterial coronaria en cuatro grupos: Grupo C (Control): 7 pcts con fracci&#243;n de eyecci&#243;n de los ventr&#237;culos izquierdo (FEVI) y derecho (FEVD) normales; Grupo 1:5 pcts con FEVD &lt; 40%; Grupo 2:9 pcts con FEVI &lt; 40%; Grupo 3:10 pcts con disfunci&#243;n de ambos los ventr&#237;culos. La FEVD y la FEVI se calcularon por medio de la angiocardiograf&#237;a con radion&#250;clidos. Las muestras para an&#225;lisis del porcentaje de col&#225;geno intersticial (%CI) se obtuvieron mediante biopsia endomioc&#225;rdica del ventr&#237;culo derecho y se colorearon con la t&#233;cnica del <italic>picrosirius red</italic>.</p>
      <p><bold>RESULTADOS:</bold> El promedio del %CI fue significativamente mayor en el grupo 3 cuando comparado al grupo-c y a los grupos 1 y 2 (30,2 &#177; 7,9% vs. 6,8 &#177; 3,3% vs. 15,8 &#177; 4,1% vs. 17,5 &#177; 7,7%, respectivamente; p = 0,0001). El %CI fue asimismo significativamente mayor en los pacientes del grupo 2 cuando comparado al control (17,5 &#177; 7,7% vs. 6,8 &#177; 3,3%, p = 0.0001). El %CI present&#243; correlaci&#243;n inversa con la FEVD (r = -0,50, p = 0.003) y la FEVI (r = -0,70, p = 0,0001).</p>
      <p><bold>CONCLUSI&#211;N:</bold> En la CMPI, el %CI se encuentra elevado en las &#225;reas no infartadas en el septo del ventr&#237;culo derecho y presenta correlaci&#243;n inversa con la funci&#243;n ventricular derecha e izquierda.</p>
      <p><bold>Palabras clave: </bold> Isquemia mioc&#225;rdica, bajo d&#233;bito card&#237;aco, funci&#243;n ventricular derecha, funci&#243;n ventricular izquierda, col&#225;geno.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia cardiaca (IC) es un s&#237;ndrome de alta prevalencia que acomete alrededor del 1% al 1,5% de la poblaci&#243;n adulta. En los d&#237;as actuales, se estima que 4,7 millones de americanos presenten IC, con un promedio de 400 mil nuevos casos a cada a&#241;o<sup>1-3</sup>. La mayor&#237;a de los casos de IC se establece por enfermedad del m&#250;sculo card&#237;aco, reconocida como cardiomiopat&#237;as. La cardiomiopat&#237;a de origen isqu&#233;mica (CMPI) es la m&#225;s frecuente, representando alrededor del 40% al 80% de todas las cardiomiopatias<sup>1,4</sup>. La CMPI presenta peor pron&#243;stico evolutivo cuando comparada a la cardiomiopat&#237;a dilatada de origen idiop&#225;tica<sup>4-7</sup>. Los posibles factores responsables de ese peor pron&#243;stico ser&#237;an la presencia de &#225;reas de isquemia mioc&#225;rdica y de fibrosis de infarto previo, que predispondr&#237;an a eventos de arritmia y al extenso proceso de remodelaci&#243;n ventricular.</p>
      <p>La activaci&#243;n del proceso de remodelaci&#243;n ventricular est&#225; relacionada con la extensi&#243;n del &#225;rea de necrosis, fibrosis y de isquemia en la regi&#243;n del infarto. Sin embargo, se ha evidenciado que los cambios morfol&#243;gicos en las &#225;reas distantes del &#225;rea infartada juegan un importante rol en el desarrollo de la remodelaci&#243;n ventricular<sup>8,9</sup>. En esas &#225;reas, encontramos fibrosis difusa perivascular, fibrosis intersticial y atrofia difusa de los mi&#243;citos<sup>10</sup>. Los cambios en la matriz mioc&#225;rdica en las zonas distantes de la cicatrizaci&#243;n del infarto representan alrededor de dos tercios de todo el tejido fibroso del coraz&#243;n y se los consideran como el mayor componente de la remodelaci&#243;n ventricular en la CMPI<sup>11,12</sup>.</p>
      <p>La relaci&#243;n de los cambios morfol&#243;gicos y morfom&#233;tricos del miocardio en el post infarto, con el desarrollo de disfunciones sist&#243;lica y diast&#243;lica del ventr&#237;culo izquierdo (VI), est&#225; bien descrita en diversos estudios de la literatura<sup>8,13-16</sup>. No obstante, la relaci&#243;n de los cambios en la matriz del miocardio no infartado con la funci&#243;n sist&#243;lica de los ventr&#237;culos derecho (VD) e izquierdo no est&#225; bien aclarada en la CMPI.</p>
      <p>En este estudio, tenemos el objetivo de evaluar la relaci&#243;n del contenido de col&#225;geno intersticial obtenido por medio de biopsia del septo del ventr&#237;culo derecho, con la funci&#243;n sist&#243;lica de los ventr&#237;culos derecho e izquierdo, en pacientes portadores de CMPI con grados variables de disfunci&#243;n ventricular.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>En el per&#237;odo de enero a diciembre de 2003, se incluyeron en el estudio, de forma consecutiva, a 31 pacientes con enfermedad arterial coronaria, evidenciada en la cineangiocoronariograf&#237;a, para investigaci&#243;n diagn&#243;stica de dolor precordial o disfunci&#243;n ventricular izquierda. Los pacientes se distribuyeron en cuatro grupos por la evaluaci&#243;n de la fracci&#243;n de eyecci&#243;n de los ventr&#237;culos izquierdo (FEVI) y derecho (FEVD) y por la angiograf&#237;a con radion&#250;clidos:</p>
      <p>&#149; Grupo control (grupo C): siete pacientes con las funciones sist&#243;licas del VI y VD preservadas.</p>
      <p>&#149; Grupo 1: cinco pacientes con disfunci&#243;n sist&#243;lica aislada del VD (FEVD &lt; 40%).</p>
      <p>&#149; Grupo 2: nueve pacientes con disfunci&#243;n sist&#243;lica aislada del VI (FEVI &lt; 40%).</p>
      <p>&#149; Grupo 3: diez pacientes con disfunci&#243;n sist&#243;lica de VI y VD.</p>
      <p>Se excluyeron a los pacientes con hipertensi&#243;n arterial pulmonar, enfermedad pulmonar obstructiva cr&#243;nica, enfermedades infiltrativas o restrictivas del miocardio, enfermedades del col&#225;geno, sospecha de miocarditis, infarto de miocardio con compromiso septal y con sospecha de disfunci&#243;n ventricular derecha por cardiomiopat&#237;a del ventr&#237;culo derecho. El protocolo de investigaci&#243;n fue aprobado por el Consejo de &#201;tica de nuestro hospital y descrito tras la obtenci&#243;n del formulario de consentimiento informado por los pacientes.</p>
      <p>Todos los pacientes realizaron evaluaci&#243;n laboratorial de bioqu&#237;mica y funci&#243;n renal, electrocardiograma (ECG) y ecocardiograma transtor&#225;cico (ECO). Los criterios de exclusi&#243;n fueron la presencia de infarto de miocardio de la regi&#243;n septal, evidenciado por el ECG y el ECO; enfermedad valvular significativa; hipertensi&#243;n arterial sist&#233;mica (presi&#243;n arterial &gt; 140 x 90 mmHg); creatinina s&#233;rica superior a 1,4 mg/dl; fibrilaci&#243;n atrial, instabilidad cl&#237;nica con menos de dos semanas y enfermedad pulmonar obstructiva cr&#243;nica.</p>
      <p>
        <bold>Cateterismo card&#237;aco</bold>
      </p>
      <p>Todos los pacientes realizaron cineangiocoronariograf&#237;a mediante la t&#233;cnica de Sones, y por medio de punci&#243;n femoral. Se tom&#243; en consideraci&#243;n como criterio para el diagn&#243;stico de enfermedad arterial coronaria la presencia de estenosis coronaria epic&#225;rdica mayor que el 50% en al menos una coronaria principal. Se realiz&#243; a&#250;n la ventriculograf&#237;a en todos los pacientes.</p>
      <p>
        <bold>An&#225;lisis de la funci&#243;n ventricular</bold>
      </p>
      <p>Las funciones ventriculares derecha e izquierda se evaluaron mediante la angiograf&#237;a con radion&#250;clidos de equilibrio y de primer paso. La fracci&#243;n de eyecci&#243;n de los ventr&#237;culos izquierdo y derecho se calcul&#243; a trav&#233;s del m&#233;todo est&#225;ndar recomendado por la Sociedad Americana de Cardiolog&#237;a Nuclear<sup>17</sup>, con los l&#237;mites inferiores de la normalidad fijados en un 40% para ambos los ventr&#237;culos. La FEVD se obtuvo por medio de la angiograf&#237;a con radion&#250;clidos de primer paso. Se utiliz&#243; una Gammac&#225;mera Siemens, modelo DIACAM, acoplada a una computadora ICON, para los ex&#225;menes de primer paso. El protocolo utilizado fue validado por Cardiovascular Nuclear Imaging Laboratory, Yale University School of Medicine<sup>18</sup>. ElTc-99m se inyect&#243; en todos los pacientes que se encontraban en reposo, para an&#225;lisis de la funci&#243;n ventricular. Se obtuvieron las im&#225;genes en la posici&#243;n supina, con el detector de la Gammac&#225;mera en la posici&#243;n oblicua anterior derecha (20&#176; a 30&#176;). El procesamiento del estudio de primer paso fue realizado por dos m&#233;dicos nucleares de modo independiente, utiliz&#225;ndose dos zonas de inter&#233;s. Los resultados promedios del an&#225;lisis de la funci&#243;n de los ventr&#237;culos derecho e izquierdo se emplearon para el an&#225;lisis estad&#237;stico. Se excluyeron los latidos con recuentos diast&#243;licos inferiores al 50% del recuento diast&#243;lico m&#225;ximo, as&#237; como las ectopias ventriculares y los latidos post ectopicos. Para fines de an&#225;lisis estad&#237;stico, la fracci&#243;n de eyecci&#243;n del ventr&#237;culo derecho normal se la consider&#243; como igual o superior al 40%.</p>
      <p>La FEVI se obtuvo por medio de la angiograf&#237;a con radion&#250;clidos planar de equilibrio con la t&#233;cnica modificada de marcaci&#243;n <italic>in vivo</italic>, utiliz&#225;ndose de 2 a 3 mg de pirofosfato esta&#241;oso, 15 minutos antes de la inyecci&#243;n de los 20 mCi de Tc-99m pertecnetato<sup>19</sup>. Se obtuvieron las im&#225;genes con el paciente en supino y con el detector a 45 grados en posici&#243;n oblicua anterior izquierda. Se consider&#243; disfunci&#243;n ventricular izquierda ante FEVI &lt; 40%.</p>
      <p>
        <bold>Biopsia endomioc&#225;rdica</bold>
      </p>
      <p>La biopsia endomioc&#225;rdica se realiz&#243; por v&#237;a percut&#225;nea, de acuerdo con la t&#233;cnica descrita por Mason<sup>20</sup>, con la utilizaci&#243;n del biotomo Cordis, con la retirada de cuatro fragmentos del septo interventricular del ventr&#237;culo derecho de cada paciente.</p>
      <p>
        <bold>An&#225;lisis histol&#243;gico y cuantificaci&#243;n del col&#225;geno intersticial</bold>
      </p>
      <p>Los fragmentos se fijaron en formol taponado al 10% y posteriormente se los incluyeron en parafina. Cortes seriados de 5 &#181;m se recolectaron en l&#225;minas y se los colorearon con hematoxilina-eosina, mediante el Tricr&#243;mico de Masson y a trav&#233;s de la t&#233;cnica Sirius Red (el 0.1% Sirius Red F3BA disuelto en &#225;cido p&#237;crico saturado, PH 2,0). Se analizaron diez campos de cada muestra con lentes objetivas de 320. El volumen de col&#225;geno se determin&#243; por medio de an&#225;lisis morfom&#233;trico cuantitativo de las sesiones coloreadas por el <italic>sirus-red</italic> y por el analizador autom&#225;tico de im&#225;genes (ImagePro Plus, versi&#243;n 4.5.1, Media Cybernetics, Silver Spring, MD, USA). Las im&#225;genes para an&#225;lisis se obtuvieron mediante c&#225;mara digital (Coolpix 990, Nikon, Jap&#243;n) acoplada a microscopio de luz Eclipse (E400, Nikon). Se analiz&#243; cada sesi&#243;n con lente objetiva de 40x. Las fibras de col&#225;geno se marcaron con color azul en luz directa, y se digitalizaron las im&#225;genes. El porcentaje de col&#225;geno intersticial (%CI) de cada campo analizado se obtuvo por la divisi&#243;n del total de toda el &#225;rea de tejido conectivo y por el total de toda el &#225;rea del tejido conectivo con la del cardiomiocito, como fue evidenciado anteriormente en diversos estudios<sup>21-24</sup>.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Para comparaci&#243;n de los datos cuantitativos entre los cuatro grupos, se realiz&#243; el an&#225;lisis de variancia de Kruskal-Wallis. La prueba de comparaciones m&#250;ltiples de Kruskal-Wallis es complementaria al an&#225;lisis de variancia y, por ello, se la utiliz&#243;, ya que algunas variables no presentaron distribuci&#243;n normal (distribuci&#243;n gaussiana). A causa del n&#250;mero peque&#241;o de casos y para comparaci&#243;n de proporciones (datos cualitativos) entre los grupos, se aplic&#243; la prueba exacta de Fisher.</p>
      <p>Para comparaci&#243;n de promedios entre dos grupos, se aplic&#243; la prueba de Mann-Whitney. La correlaci&#243;n entre el porcentaje de col&#225;geno con las variables num&#233;ricas se evalu&#243; por medio del coeficiente de correlaci&#243;n de Spearman. La curva ROC (<italic>receiver operator characteristic</italic>) se la utiliz&#243; para establecer el mejor punto de corte del %CI, que predice la disfunci&#243;n ventricular derecha e izquierda. El criterio de determinaci&#243;n de significancia adoptado fue el nivel del 5%. El an&#225;lisis estad&#237;stico se proces&#243; por medio del <italic>software</italic> estad&#237;stico SAS<sup>&#174;</sup> System.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>
        <bold>Caracter&#237;sticas de los pacientes</bold>
      </p>
      <p>Las caracter&#237;sticas cl&#237;nicas de los pacientes est&#225;n presentadas en la <xref ref-type="table" rid="es_09t1-body3">Tabla 1</xref>. Ninguna diferencia significativa se observ&#243; entre los cuatro grupos con relaci&#243;n a las variables cl&#237;nicas y demogr&#225;ficas, a excepci&#243;n de la menor incidencia de tabaquismo en el Grupo 3. La mayor&#237;a de los pacientes estaba utilizando inhibidores de la enzima de conversi&#243;n y betabloqueantes, sin demostrar diferencias significativas entre los grupos en cuanto a la posolog&#237;a de los medicamentos.</p>
      <p content-type="asset">
        <table-wrap id="es_09t1-body3">
          <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gt01-es.jpg"/></table-wrap>
      </p>
      <p>
        <bold>Enfermedad arterial coronaria</bold>
      </p>
      <p>La mayor parte de los pacientes (84%) presentaba lesiones de dos o tres vasos. La coronaria descendente anterior fue la m&#225;s acometida. No se observ&#243; ninguna diferencia entre los cuatro grupos respecto a la presencia de lesi&#243;n proximal de la coronaria descendente anterior y la coronaria derecha (p = 0,91) <xref ref-type="table" rid="t2-body3">Tabla 2</xref>.</p>
      <table-wrap id="t2-body3">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gt02-es.jpg"/></table-wrap>
      <p>
        <bold>An&#225;lisis de la funci&#243;n ventricular</bold>
      </p>
      <p>La FEVI promedio en los cuatro grupos fue de 51,5 &#177; 8,5 en el Grupo Control, 50,6 &#177; 8,8, 27,9 &#177; 5,1 y 21,7 &#177; 4,7% en los grupos 1 a 3, respectivamente. La FEVD promedio en los cuatro grupos fue, respectivamente, de 42,4 &#177; 4,7, 28,2 &#177; 2,7, 50,3 &#177; 5,1 y 22,0 &#177; 6,5%. No se observ&#243; diferencia significativa de la FEVI entre los grupos con disfunci&#243;n biventricular y con disfunci&#243;n aislada del ventr&#237;culo izquierdo (21,7 &#177; 4,7% vs. 27,9 &#177; 5,1, p = 0,10). De igual manera, no se observ&#243; diferencia significativa respecto a la FEVD entre los grupos con disfunci&#243;n biventricular y con disfunci&#243;n aislada del ventr&#237;culo derecho (28,2 &#177; 2,7 vs. 22,0 &#177; 6,5%, p = 0,10).</p>
      <p>
        <bold>An&#225;lisis de la fracci&#243;n del col&#225;geno intersticial</bold>
      </p>
      <p>El valor promedio del %CI est&#225; presentado en la <xref ref-type="fig" rid="f1-body3">Figura 1</xref>. El grupo de pacientes con disfunci&#243;n biventricular present&#243; mayor %CI en comparaci&#243;n a los grupos control y la disfunci&#243;n aislada de los ventr&#237;culos derecho e izquierdo (30,2 &#177; 7,9 vs. 6,8 &#177; 3,3, 15,8 &#177; 4,1 e 17,5 &#177; 7,7%, respectivamente; p = 0,0001). Los pacientes con disfunci&#243;n ventricular izquierda aislada presentaron un mayor %CI que el Grupo Control (17,5 &#177; 7,7 vs. 6,8 &#177; 3,3%, p = 0,0001), pero sin diferencia cuando comparado al grupo con disfunci&#243;n aislada del ventr&#237;culo derecho (17,5 &#177; 7,7 vs. 15,8 &#177; 4,1, p = 0,58). El grupo con disfunci&#243;n aislada del ventr&#237;culo derecho present&#243; una tendencia a un mayor %CI en relaci&#243;n al observado en el grupo control (15,8 &#177; 4,1 vs. 6,8 &#177; 3,3, p = 0,08) (<xref ref-type="fig" rid="f2-body3">Fig. 2</xref>).</p>
      <fig id="f1-body3">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf01-es.jpg"/></fig>
      <fig id="f2-body3">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf02-es.jpg"/></fig>
      <p>
        <bold>Correlaci&#243;n entre el %CI y la funci&#243;n ventricular</bold>
      </p>
      <p>Observamos una correlaci&#243;n lineal inversa significativa entre el porcentaje de col&#225;geno y la FEVD (r = -0,50; p = 0,003, n = 31) y la FEVI (r =-0,70; p = 0,0001, n = 27). Ello significa que cuanto mayor sea el porcentaje de col&#225;geno, menores ser&#225;n la FEVD y la FEVI, lo que se puede observar en las <xref ref-type="fig" rid="f3-body3">Figuras 3</xref> y <xref ref-type="fig" rid="f4-body3">4</xref>.</p>
      <fig id="f3-body3">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf03-es.jpg"/></fig>
      <fig id="f4-body3">
        <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf04-es.jpg"/></fig>
      <p>
        <bold>An&#225;lisis de la curva ROC</bold>
      </p>
      <p>El mejor punto de corte del %CI para la asociaci&#243;n con FEVI <underline>&lt;</underline> 40% fue del 18,3%, con una sensibilidad del 70,5% y especificidad del 90,0%, y &#225;rea de curva ROC de 0,87 (IC95%:0,7-0,9; p = 0,0001) (<xref ref-type="fig" rid="es_09f5-body3">Figura 5 a</xref>). Para la asociaci&#243;n con FEVD <underline>&lt;</underline> 40%, el punto de corte del %CI fue del 12,9%, con una sensibilidad del 82,0% y especificidad del 64,2%, y &#225;rea de curva ROC de 0,77 (IC95%:0,59-0,9; p = 0,0009) (<xref ref-type="fig" rid="es_09f5-body3">Fig. 5 b</xref>).</p>
      <p content-type="asset">
        <fig id="es_09f5-body3">
          <graphic xlink:href="1678-4170-abc-92-01-0054-00009-gf05-es.jpg"/></fig>
      </p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Este es el primer estudio en la literatura, realizado en humanos, que evidenci&#243; una correlaci&#243;n directa entre los niveles de col&#225;geno intersticial en el ventr&#237;culo derecho, con la funci&#243;n ventricular derecha e izquierda, en pacientes con cardiomiopat&#237;a isqu&#233;mica. Observamos una correlaci&#243;n lineal entre el %CI en la regi&#243;n no infartada y el grado de disfunci&#243;n ventricular de los ventr&#237;culos derecho e izquierdo. El %CI se presentaba elevado en 4,4 veces en los pacientes con disfunci&#243;n biventricular; en 2,5 veces en los con disfunci&#243;n aislada del ventr&#237;culo izquierdo; y en 2,3 veces en los individuos con disfunci&#243;n ventricular derecha aislada, cuando comparados a los pacientes con funci&#243;n ventricular preservada, lo que evidencia la correlaci&#243;n inversa del %CI con la FEVI y FEVD. La asociaci&#243;n de la disfunci&#243;n ventricular con el grado de proliferaci&#243;n de col&#225;geno intersticial fue reforzada en la demostraci&#243;n de una relaci&#243;n lineal inversa entre el porcentaje de proliferaci&#243;n del col&#225;geno y la FEVD y FEVI (<xref ref-type="fig" rid="f3-body3">Fig. 3</xref> y <xref ref-type="fig" rid="f4-body3">4</xref>). Tomando en cuenta el an&#225;lisis de la relaci&#243;n de los diversos porcentajes de col&#225;geno intersticial con la funci&#243;n ventricular, fue posible determinar un punto de corte de porcentaje de col&#225;geno intersticial para el pron&#243;stico de desarrollo de disfunci&#243;n ventricular derecha y de disfunci&#243;n ventricular izquierda del 12,9% y del 18%, respectivamente; con alta sensibilidad (82,0% y 70,5%, respectivamente) y especificidad (64,2% y 90,0%, respectivamente), y con las &#225;reas de la curva ROC de 0,87 y 0,77, respectivamente. Ello, por tanto, se&#241;ala la fuerte correlaci&#243;n de esos valores de corte del %IC para la discriminaci&#243;n de la presencia de disfunci&#243;n ventricular (<xref ref-type="fig" rid="es_09f5-body3">Fig. 5 a</xref> y <xref ref-type="fig" rid="es_09f5-body3">b</xref>).</p>
      <p>Estudios en animales y humanos han demostrado que las alteraciones en la trama de col&#225;geno intersticial del miocardio en la cardiomiopat&#237;a isqu&#233;mica y no isqu&#233;mica juegan un importante rol en el desarrollo de la disfunci&#243;n ventricular. Sobre todo, la posibilidad de la deposici&#243;n de col&#225;geno en el intersticio ser un factor primario para el desarrollo de la disfunci&#243;n mioc&#225;rdica y no solamente un marcador<sup>8,9,12-16,25,26</sup>. Esa posibilidad es enfatizada por estudios que evidencian que la remodelaci&#243;n post infarto de miocardio est&#225; asociada al incremento de la fibrosis intersticial en el miocardio no infartado; adem&#225;s de &#233;sta &#250;ltima correlacionarse con la progresiva rigidez mioc&#225;rdica y la consecuente disfunci&#243;n sist&#243;lica y diast&#243;lica<sup>12,13,26-28</sup>. Otra evidencia que fortalece nuestros hallazgos de mayor proliferaci&#243;n de CI en la disfunci&#243;n biventricular es el hecho de haber una mayor producci&#243;n de angiotensina en el miocardio de pacientes con disfunci&#243;n ventricular derecha por hipertensi&#243;n arterial pulmonar<sup>29</sup>. La dificultad en confirmarse la asociaci&#243;n del grado de disfunci&#243;n ventricular derecha o izquierda al nivel de proliferaci&#243;n del CI reside en la ausencia de estudios en la literatura que abarcan el an&#225;lisis del col&#225;geno en seres humanos vivos, con grado de disfunci&#243;n ventricular y, sobre todo, con la funci&#243;n ventricular derecha. Uno de los factores que puede justificar esa falta de evidencias es la dificultad presentada por los m&#233;todos diagn&#243;sticos de evaluar con una exactitud las funciones sist&#243;lica y diast&#243;lica del ventr&#237;culo derecho.</p>
      <p>Pauschinger et al.<sup>25</sup> evidenciaron, en pacientes con cardiomiopat&#237;a dilatada, una mayor proliferaci&#243;n de col&#225;geno intersticial en los individuos con FEVI &lt; 50%, cuando comparados a los pacientes con FEVI &gt; 50% (4,3 &#177; 0,1% vs. 2,7 &#177; 0,9 %, p &lt; 0,0035), lo que estaba asociado al aumento de la relaci&#243;n entre los col&#225;genos de los tipos I e III.</p>
      <p>En la cardiomiopat&#237;a dilatada no isqu&#233;mica tambi&#233;n se observa una mayor proliferaci&#243;n del col&#225;geno intersticial<sup>30</sup>, pero en un nivel inferior al de la cardiomiopat&#237;a isqu&#233;mica<sup>12,13</sup>. Ese nivel m&#225;s acentuado de proliferaci&#243;n del col&#225;geno en la cardiomiopat&#237;a isqu&#233;mica resultar&#237;a tanto del proceso de remodelaci&#243;n ventricular, inducido por el infarto de miocardio, como tambi&#233;n del est&#237;mulo tr&#243;fico de la isquemia mioc&#225;rdica<sup>31,32</sup>. La proliferaci&#243;n excesiva del col&#225;geno intersticial provoca fibrosis mioc&#225;rdica con consecuente rigidez mioc&#225;rdica y disfunci&#243;n diast&#243;lica, y subsiguiente compromiso de la funci&#243;n sist&#243;lica<sup>8,33-36</sup>. Weber y Brilla<sup>14</sup> sugieren que la deposici&#243;n de col&#225;geno intersticial es el principal determinante de la reducci&#243;n de la capacidad de relajaci&#243;n ventricular. La acumulaci&#243;n de col&#225;geno est&#225; tambi&#233;n relacionada a la gravedad cl&#237;nica de la insuficiencia cardiaca, grado de compromiso hemodin&#225;mico, hiponatremia y necesidad de transplante cardiaco<sup>37</sup>. En cambio, los pacientes hipertensos tratados con inhibidores da enzima de conversi&#243;n o bloqueantes del receptor de la angiotensina evidenciaron una reducci&#243;n de la fibrosis e hipertrofia ventricular, independientemente de la reducci&#243;n de la presi&#243;n arterial, con mejora de las funciones sist&#243;lica y diast&#243;lica ventriculares, reducci&#243;n de la masa ventricular, arritmias cardiacas y mejora de los s&#237;ntomas cl&#237;nicos<sup>38-40</sup>.</p>
      <p>Esos hallazgos sugieren que la proliferaci&#243;n del col&#225;geno intersticial en la cardiomiopat&#237;a isqu&#233;mica opera como factor primario determinante de la disfunci&#243;n ventricular y no s&#243;lo como un marcador del grado de remodelaci&#243;n ventricular. En los pacientes con cardiomiopat&#237;a isqu&#233;mica, se observa que el contenido de col&#225;geno se encuentra elevado no s&#243;lo en el &#225;rea del miocardio infartado, sino que tambi&#233;n est&#225;, sobre todo, en las regiones no infartadas del mioc&#225;rdio<sup>8,12,16</sup>, lo que fue cuestionado por Marijianowski et al.<sup>41</sup> y validado por varios otros autores<sup>37,42</sup>.</p>
      <p>Nuestros hallazgos tienen importantes implicaciones en la pr&#225;ctica cl&#237;nica, ya que evidenciamos que en las formas menos avanzadas de disfunci&#243;n ventricular hay un incremento significativo de la proliferaci&#243;n del col&#225;geno y que su progresi&#243;n est&#225; directamente relacionada al agravamiento de la disfunci&#243;n y el grado de remodelaci&#243;n ventricular. Esos hallazgos sugieren que la terap&#233;utica de inhibici&#243;n de la producci&#243;n de col&#225;geno con inhibidores de la enzima de conversi&#243;n, bloqueantes de los receptores de angiotensina y antagonistas da aldosterona, en fases menos avanzadas de disfunci&#243;n ventricular, puede resultar como beneficio en la reducci&#243;n de la progresi&#243;n de la remodelaci&#243;n ventricular y de la mortalidad, como ya demostrado en la disfunci&#243;n ventricular avanzada<sup>43-47</sup>.</p>
      <p>
        <bold>Limitaciones del estudio</bold>
      </p>
      <p>Se deben tomar en consideraci&#243;n algunas limitaciones de nuestro estudio. La mayor parte de los pacientes estaba utilizando inhibidores de la enzima de conversi&#243;n, y ello puede haber afectado el contenido de col&#225;geno en funci&#243;n de su actuaci&#243;n como reductor de la fibrosis mioc&#225;rdica. Sin embargo, no hubo diferencia entre los grupos en cuanto al uso de la medicaci&#243;n y con relaci&#243;n a su posolog&#237;a. Otra limitaci&#243;n de este estudio fue la obtenci&#243;n de las muestras tisulares por medio de biopsia endomioc&#225;rdica del septo del ventr&#237;culo derecho, lo que limit&#243; nuestra evaluaci&#243;n a solamente una regi&#243;n ventricular, sin un an&#225;lisis de la distribuci&#243;n en las otras regiones ventriculares. Esa clase de an&#225;lisis, no obstante, s&#243;lo ser&#237;a posible en corazones de pacientes explantados con insuficiencia cardiaca terminal, lo que no era el objetivo del presente estudio. Otro factor limitante fue la ausencia de un grupo control de pacientes sin enfermedad coronaria con biopsia endomioc&#225;rdica, que, por razones &#233;ticas, no fue posible realizarse. Sin embargo, el contenido promedio de col&#225;geno en el grupo de nuestros pacientes con funci&#243;n ventricular preservada fue semejante al observado en estudios de pacientes con coraz&#243;n normal, sin enfermedad coronaria, de muestras obtenidas a trav&#233;s de la biopsia del septo del VD<sup>48</sup> y de la pared libre del VI<sup>49</sup>. El an&#225;lisis de la relaci&#243;n de los subtipos del col&#225;geno tipo I/III se nos podr&#237;a suministrar informaciones respecto al potencial de reversibilidad de la fibrosis mioc&#225;rdica y al potencial de mejora evolutiva de la funci&#243;n ventricular, como fue sugerido por el estudio de Pauschinger et al.<sup>25</sup>.</p>
      <p>Por fin, no evaluamos la presencia de isquemia mioc&#225;rdica, la que podr&#237;a influir en el grado de proliferaci&#243;n del col&#225;geno, aunque la extensi&#243;n de la enfermedad coronaria evaluada por la coronariograf&#237;a era semejante en los grupos de pacientes.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Concluimos que en pacientes con cardiomiopat&#237;a isqu&#233;mica ocurre un aumento de col&#225;geno en la regi&#243;n no infartada del septo del ventr&#237;culo derecho, que se correlaciona inversamente con el grado de disfunci&#243;n sist&#243;lica de los ventr&#237;culos derecho e izquierdo.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de tesis de Doctorado de Marcelo Westerlund Montera, por la Universidad de S&#227;o Paulo.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
